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Chapter 1 
General introduction 
Cellular functions are determined by integrative interactions between various constituents, 
i.e., genes, transcripts, proteins, and metabolites. Thus, it is important to study these interactions 
to understand the whole biological system. Genetic perturbations are often used to investigate 
the contribution of individual components. One of such components is a transcription factor. 
Transcription factors are the regulatory proteins that interact with DNA to either promote or 
suppress gene expression. Due to the importance of transcription factors in gene regulation, 
they have been widely studied and much attention has been paid regarding the roles of 
transcription factors. In this thesis, the effects of transcription factor-related gene deletion 
towards metabolic levels were studied, using the budding yeast Saccharomyces cerevisiae as a 
model organism. 
 
1.1. Yeast as a model organism 
1.1.1. Yeast transcription factors 
Since its completion of genome sequencing in 1996 1, research on yeast Saccharomyces 
cerevisiae has shifted from merely decoding the DNAs to understanding the function of the 
genes, i.e., functional genomics. S. cerevisiae has been used for a model eukaryote for its 
convenience to handle and manipulate genetically, fast growth and short generation time. 
Although this single-celled eukaryote is much simpler than multicellular organisms, the cell 
cycle is very similar to the cell cycle in humans. Up to 30% of genes implicated in human 
disease may have orthologs in the yeast proteome 2, and many studies regarding aging, 
apoptosis, metabolism and gene expression have been performed using yeasts 3. Additionally, 
S. cerevisiae is an industrially important microorganism, used in many fields, from food 
industry to the production of chemicals. The use of S. cerevisiae has been assisted by vast 
literatures and curated databases. Examples are SGD (Saccharomyces Genome Database, 
http://www.yeastgenome.org/), YEASTRACT (Yeast Search for Transcriptional Regulators 
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And Consensus Tracking, http://www.yeastract.com/) and YMDB (Yeast Metabolome 
Database, http://www.ymdb.ca/). 
Cells employ an elaborate and complex gene expression system that allows them to 
reprogram their genetic makeup in response to different environments and growth demands. At 
the forefront of this control system lies transcription factors (TFs). TFs are the regulatory 
proteins that initiate or suppress gene expression, directly by binding to the promoter regions 
in the DNA, or indirectly by forming complex with other TFs. For decades, researchers have 
been interested in the function and regulation of TFs; biotechnologically this knowledge can 
help in the improvement of industrially important microbial strains as demonstrated by global 
transcriptional machinery engineering (gTME) technique 4,5, and clinically TFs themselves can 
serve as potential drug targets such as estrogen receptors and c-Myc for cancer therapies 6,7, and 
generally proposed for new drug discovery 8,9. 
Yeast has been used to study eukaryotic transcriptional regulatory mechanisms as well. 
Transcriptional regulatory mechanisms are fundamentally similar in eukaryotes, in which 
complex promoters with multiple protein binding sites are typical 10. Components of the basal 
RNA polymerase II machinery and several general transcription factors have been determined, 
and the yeast system has been the leading model for these discoveries 11.  
Generally, TFs can be categorized based on their transcription modes or protein structures 
(DNA binding domain motifs). In terms of transcription modes, TFs can be divided into three 
classes; 1) core machinery transcriptional component (i.e., basal transcription factors) that binds 
to the DNA promoter region, examples are the TATA-binding proteins; 2) activator or repressor 
proteins (i.e., sequence-specific binding proteins) that recognize specific DNA sequences and 
directly bind to the UAS (upstream activation sequence) or URS (upstream repression 
sequence); and 3) co-activator proteins that do not by themselves bind to the DNA but instead 
interact with other TFs to activate gene expression machinery. 
On the basis of DNA-binding domain (DBD), TFs are categorized into three general classes: 
zinc-stabilized, zipper type and helix-turn-helix (Fig. 1-1, reviewed by Hahn and Young, 
201111). In the zinc-stabilized class, the TFs can be further classified into three sub-classes: 
C2H2 zinc fingers, C6 (zinc knuckle or Zn2Cys6 binuclear zinc cluster) and C4 (or GATA 
fingers). C2H2 and C4 are ubiquitous while C6 is unique to fungi. The zinc-stabilized DBD is 
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the most abundant in all organisms, and as the name indicates, requires Zn2+ to stabilize. At 
least one TF in yeast, i.e., Ace1/Cup2 is stabilized by Cu2+. There are 53 members in C2H2 
(e.g., Adr1, Mig1, Zap1), 55 members in C6 (e.g., Gal4, Hap1, Leu3) and 5 members in C4 
(Gln3, Gat1, Nil1, Dal80, Ash1) proteins. 
The second most abundant TF class is the zipper type. DBD of this class is characterized 
by a dimerization motif and a basic region. There are two sub-classes of zipper type: bZIP (basic 
leucine zippers; 14 members, e.g., Gcn4, Yap1, Sko1) and bHLH (basic helix-loop-helix; 9 
members, e.g., Ino2, Ino4, Rtg1, Rtg3). Zipper type TFs form homo- or heterodimers, a feature 
that enables multi-regulatory control of transcription. Consequently, zipper type TFs involve in 
many processes including cell development and stress responses.  
The third class, HTH (helix-turn-helix; 8 members, e.g., Matα1, Matα2, Mata1), also forms 
homo- and heterodimers. A classical HTH protein in yeast is Matα2, which, together with 
Mcm1, represses a-specific genes in Matα haploids. The forkhead (Fkh) transcription factors 
(Mcm1, Fkh1, Fkh2, Mcm1) and the heat shock factor (HSF) are related to the HTH proteins. 
However, there are also TFs that lack a DBD motif, such as Met4 and Swi6, while other 
TFs such as Gcr1 and Dal81 have a DBD that is dispensable. These proteins form a heterodimer 
and interact with DNA through their binding partner. 
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Fig. 1-1. Classification of yeast transcription factors according to DNA binding domain motifs. (A) 
C2H2 zinc fingers of Adr1; (B) C6 (zinc knuckle) of Gal4; (C) bZIP structure of Gcn4; (D) bHLH of 
Pho4; (E) helix-turn-helix of Matα2 and winged helix of Mcm1. (Hahn and Young, 201111) 
 
1.1.2. Transcription factors and gene regulatory studies 
Because of the important role of TFs in gene expression, various studies have been 
undertaken to find which TFs are involved in the expression of a certain set of genes, when and 
why the genes are expressed, and more importantly the consequences of such gene expression. 
Large scale gene-protein and protein-protein interactions and transcript analysis have 
contributed to the vast knowledge of TFs, following current advancement in microarray and 
ChIP techniques. Several strategies commonly employed are; computer-based approach such 
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as development of algorithms that seek conserved promoter elements or common sequence 
elements in the promoters of co-expressed genes 12,13, microarray-based biochemical 
approaches that identifies binding and the sequence of individual TFs 14–16, and ChIP-chip 17–19 
that identifies sequences bound by a TF in vivo.  
Despite the large amount of studies, the understanding of TFs is far from complete due to 
the complex nature of gene regulation; multiple-stage control and modularity element of TFs, 
post-transcriptional and post-translational modifications, and lack of information regarding the 
signaling molecules itself and intercellular communication that all lead to gene expression. 
Particularly, the connection between the transcript and protein to final phenotypic change is 
lacking, and thus an alternative approach to studying TF regulation is necessary. Although 
transcriptomics can analyze genome-wide gene expression levels and many large-scale genetic 
perturbations using microarrays have been performed 16,20,21, transcript levels are known to be 
unstable, and it is difficult to compare such large data generated across different technology 
platforms, genetic backgrounds and degrees of replication 22. Moreover, while the expression 
levels of genes encoding an enzyme can be relatively easy to infer (for example, the 
upregulation of an enzyme catalyzing a biochemical reaction can be interpreted as increased 
products and decreased substrates), interpretation of genes encoding e.g., a transporter or a 
permease may not be as simple. Therefore, additional parameters (in this case, metabolite 
levels) can help in the interpretation of gene transcription process and its effects to the cells. 
 
1.1.3. S. cerevisiae central carbon metabolism 
Yeast has been the subject of study since the 17th century, when it was identified by a Dutch 
lens maker, Antonie van Leeuwenhoek who first developed the microscope. Today, it is still 
one of the important microorganisms, due to its industrial relevance in many applications, from 
bread to winemaking, to the production of chemicals. S. cerevisiae is a Crabtree positive yeast, 
a facultative anaerobe, able to perform alcoholic fermentation of glucose under fully aerobic 
conditions. The adaptation of S. cerevisiae’s metabolism under different conditions represents 
an excellent model for studying metabolic regulation. 
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At the center of metabolic network lies the central carbon metabolism. Central carbon 
metabolism in S. cerevisiae refers to the breakdown of carbon source (typically glucose), to 
produce biosynthetic precursors for biomass formation and generate energy required for growth. 
It comprises both catabolic (breakdown of large molecules, energy-producing) and anabolic 
(building up of large molecules from smaller units, energy-requiring) pathways. Central carbon 
metabolism includes; a) glycolysis: the breakdown of sugar to pyruvate, b) pentose phosphate 
pathway, PPP: used for the generation of NADPH, c) tricarboxylic acid cycle, TCA or Krebs 
cycle: generating FADH2 and NADH, which are then used for ATP production under oxidative 
phosphorylation, and d) glyoxylate cycle: an anaplerotic pathway that ensures continuous 
supply of intermediates when TCA cycle is compromised, and of growth in 2- and 3-carbon 
molecules. Related to glycolysis is gluconeogenesis, the anabolic pathway to produce glucose 
from non-carbohydrate carbon substrates such as pyruvate, lactate, glycerol, glucogenic amino 
acids, and fatty acids. Fig. 1-2 illustrates the central carbon metabolism of S. cerevisiae.  
The central carbon metabolism is highly conserved among various organisms and holds the 
key to understanding cell regulation under different metabolic states, either caused by genetic 
or environmental perturbations. Thus, examining alterations at the central metabolic level 
signifies a fundamental step in functional genomics studies.  
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Fig. 1-2. Central carbon metabolism of S. cerevisiae 
 
1.2. Metabolomics 
1.2.1. General concept 
Biological systems are comprised of four main biochemical components, i.e., genes, 
transcripts, proteins and metabolites. The complete collection of each component is referred to 
as genome, transcriptome, proteome and metabolome (Fig. 1-3). These components interact 
with each other in an integrative manner to determine cellular phenotypes. Systems level studies 
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of these biological components on a global scale has been driven by various ‘omics’ 
technologies, each built based on the individual component properties. These techniques are 
driven by high-throughput approaches that yield a large set of data that are often challenging to 
analyze, but present a holistic view of cellular functions. Table 1-1 summarizes ‘omics’ 
technologies. Besides these four main techniques, several other branched ‘omics’ such as 
fluxomics (measurement of the ensemble of metabolic fluxes) and lipidomics (comprehensive 
profiling of lipid molecules) have also been described. 
 
 
Fig. 1-3. The central dogma of biology, where genes are transcribed into mRNA, which is further 
translated into protein, which then participates in a metabolic pathway to give rise to a certain metabolite. 
This schematic diagram also captures the role of transcription factors as the forefront molecule in gene 
transcription process. By measuring the metabolic alteration following a transcription factor 
perturbation, elucidation of the TF function can be achieved. 
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Table 1-1. The ‘omics’ technologies 
Omics Description Methods Applications 
Genomics Comprehensive study of a 
genome, including protein 
coding genes, regulatory 
elements and non-coding 
sequences 
 
・ Gene sequencer Genome sequence 
information 
Transcriptomics Quantitative study of mRNA 
(transcript) expression levels 
・ Hybridization 
arrays 
(microarrays) 
・ RNA sequencer 
 
Analysis of differential 
gene expression, gene-
gene network 
 
Proteomics Analysis of protein content 
and abundances 
・ 2D-PAGE gels 
・ Protein arrays 
・ MALDI-TOF, 
LC/MS 
Identification of 
protein function, 
protein-protein 
interactions 
 
Metabolomics Comprehensive study of 
metabolites and metabolic 
network 
・ GC/MS, LC/MS 
・ NMR 
Identification and 
quantification of key 
metabolites, 
elucidation of 
metabolic behavior 
 
Metabolites hold a special position in systems biology since they are most downstream 
products of gene expression process. Transcripts or proteins can undergo various post-
transcriptional and post-translational modifications, and thus the changes in transcript or protein 
abundances do not necessarily lead to an equal change in phenotype. In contrast, metabolites 
represent the final outcome of gene expression, and thus are the ultimate readouts of a 
phenotype. Moreover, metabolites also serve as the building block for genes and transcripts 
(nucleotides), proteins (amino acids) and organelles, and well-preserved among different 
organisms. In yeast, it is estimated that there are approximately 600-1000 metabolites 23, a 
number far less than the number of genes or proteins. However, this also means that there is a 
higher complexity since metabolites have no direct one-to-one relation with genes/proteins and 
involve in various biochemical reactions simultaneously. 
Generally, metabolomics strategies can be largely divided into; targeted analysis, 
metabolite profiling, metabolomics and metabolic fingerprinting 24,25. Targeted analysis 
approach is used when the metabolites of interest are known, and involves quantification of the 
metabolites. Metabolite profiling, also called semi-targeted approach, is the quantitative or 
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qualitative determination of a group of related compounds or of specific metabolic pathways. 
Metabolomics (qualitative and quantitative analysis of all metabolites) and metabolic 
fingerprinting (sample classification by rapid, global analysis), are related to non-targeted 
analysis, which typically aims to profile all metabolites, so-called ‘measure everything’ 
approach 26. In this study, a semi-targeted metabolomics approach is employed. Targeted and 
semi-targeted analyses deal with a defined set of metabolites; the difference is mainly in terms 
of the number of metabolites measured, typically around 20 for targeted and a hundred to a few 
hundreds for semi-targeted 26. The number of metabolites that can be measured is often limited 
by the number of commercially available authentic metabolite standards. Semi-targeted 
approach allows for a wider coverage of metabolites than targeted approach, consequently 
higher chance of finding significant metabolites, with higher accuracy and quantification ability 
than non-targeted approach. Thus, a good compromise between metabolite numbers and 
quantification ability is obtained. 
 
1.2.2. Metabolomics approach in this study 
To elucidate the complex metabolic alteration following the deletion of a transcription 
factor, ideally all of the metabolites are measured. However, the diverse chemical properties of 
metabolites, including molecular weight, polarity, hydrophobicity, volatility, and chemical 
structures, make simultaneous measurement technically demanding 26. Recently, ion pairing 
liquid chromatography/mass spectrometry (LC/MS) has been developed as a widely-targeted 
metabolome analysis platform that covers a wide range of metabolites 27–31. Particularly, highly 
polar intermediates from central metabolism, such as sugar phosphates and nucleotide 
triphosphates, can be measured with good reproducibility using this platform. By adding an ion 
pairing reagent in the mobile phase, the ability to retain highly polar metabolites that otherwise 
are eluted near the void volume in regular reversed-phase LC is improved. Moreover, ion 
pairing LC has a better separation and higher signals compared to hydrophilic interaction 
chromatography (HILIC) in the analysis of central metabolites 32. Therefore, ion pairing LC/MS 
fits as an analysis platform for metabolic profiling of transcription factor deletion mutants in 
this study. The use of triple quadrupole mass spectrometry (MS/MS) helps to separate isomers 
with an additional filter at the third quadrupole and improve selectivity. 
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In this study, ion pairing LC/MS is used as the main analysis platform for metabolite 
profiling. Tributyl amine (TBA) is added to the mobile phase as an ion pairing reagent for the 
separation of anionic metabolites. In addition, regular reversed-phase LC/MS and GC/MS were 
also used as complementary platforms for the measurement of important metabolites undetected 
or having poor performance in ion pairing LC/MS. 
The overall workflow for this study is depicted in Fig. 1-4. First, analytical platform 
dedicated for the profiling of yeast samples was developed. This step includes analysis of 
standard metabolites, analysis of a reference strain and construction of an in-house yeast 
metabolite library. Next, metabolic profiling of selected yeast strains was carried out, using the 
established analysis platform. In this step, yeast samples were obtained after culture and 
metabolite extraction, then subjected to metabolite measurement. In the subsequent step, peak 
identification was performed, after which a peak list table (metabolome dataset) was obtained. 
Finally, after suitable data pre-processing (normalization and scaling), multivariate data 
analysis was conducted. 
 
Fig. 1-4. Schematic diagram of experimental workflow and strategies employed in this study. 
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1.3. Research objective 
As described in Section 1.1.2, the knowledge of transcription factors still has a long way to 
go. Particularly, the missing link between TFs to final phenotypic change needs to be addressed. 
To fill the gap of the connection between TFs and phenotype (cellular composition, 
physiological appearances, growth competency etc.), the most downstream product of gene 
expression i.e., metabolites should be characterized. Metabolites can serve as an indicator of 
the effects of such gene up- or down- regulation caused by TF deletion. Therefore, metabolite 
profiling fits as an excellent approach for studying metabolic alteration in TF deficient strains.  
In this study, a dispensable activator/repressor group of TFs (non-essential for growth) is 
dealt with. Intermediates from the central carbon metabolism and related amino acid 
biosynthetic pathways are measured following TF-gene perturbation, and the correlations 
between TF-metabolite are derived. The overall goal of this study is to deepen the knowledge 
of TFs and transcriptional regulation by examining metabolic alteration levels. To achieve this 
goal, the following strategies were set; 
1. Demonstrate the utility of metabolomics in finding novel TF-metabolite correlations using 
a model transcription factor complex 
2. Perform a global metabolome analysis for a comprehensive set of TF deletion strains 
3. Use the obtained TF-metabolite correlation data to suggest possible new associations 
and/or further enhance existing knowledge 
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1.4. Outline of the thesis 
This thesis regards the effects of transcription factor deletion towards metabolic alteration. 
Specifically, the correlations between a TF gene and metabolites were investigated. In Chapter 
1, general introduction and research background are presented. In particular, yeast transcription 
factors and metabolomics techniques are discussed. In Chapter 2, metabolic profiling of two 
representative basic helix-loop-helix (bHLH) transcription factors Rtg1 and Rtg3 yeast mutant 
is demonstrated as a proof-of-principle of the utility of metabolomics approach in finding TF-
metabolite correlations. Using exploratory data analysis, information regarding important 
metabolites that discriminate between mutant and wild-type strain was obtained. Of note was 
the identification of metabolites/metabolic pathways previously unidentified from other 
approaches, and metabolic changes in the early growth phase. In Chapter 3, a global 
metabolome analysis was performed for 154 TF deletion strains. Characterization using 
hierarchical clustering analysis (HCA) and differential analysis showed that the strains can be 
categorized according to their metabolic phenotype; some clustering shared similar known 
function or the same gene annotation, in agreement with previous findings, whereas some 
demonstrated new associations. These results illustrate that metabolomics can assist in the 
generation of new working hypotheses of TF functional analysis based on TF-metabolite 
correlations, which were not necessarily evident from transcript data. Also discussed are issues 
regarding data normalization and correction of batch-to-batch variation, a prevalent problem in 
mid- to large-scale metabolomics studies. Finally, in Chapter 4, general conclusions and future 
perspectives are presented. 
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Chapter 2 
Metabolic profiling of retrograde pathway transcription factors 
Rtg1 and Rtg3 knockout yeast 
 
2.1. Introduction 
In this chapter, as a proof-of-principle, two representative transcription factors were chosen 
for metabolic profiling. To ensure that the TF deletion will result in a substantial alteration in 
metabolite levels (so that the difference between wild-type and disruptant strains can be clearly 
seen in terms of metabolic profile), TFs that are known to affect metabolic pathways were 
selected. In this regard, Rtg1 and Rtg3, two mitochondrial retrograde pathway regulators that 
have several target genes in the tricarboxylic acid (TCA) cycle, fit this purpose. Furthermore, 
mitochondrial retrograde pathway is conserved in many organisms including humans 33,34. 
Rtg1 and Rtg3 are two basic helix-loop-helix (bHLH) transcription factors found in yeast 
Saccharomyces cerevisiae and are known regulators of mitochondrial retrograde (RTG) 
response 47. bHLH proteins were chosen as they represent a large family of regulators, 
conserved in all eukaryotes 35–37 and have been widely studied. They engage in diverse 
metabolic pathways including phosphate utilization, amino acid biosynthesis, and glycolysis. 
Owing to the characteristic dimer formation of bHLH proteins, it is expected that they involve 
in various metabolic pathways and are inter-connected with each other as well as other 
transcription factors 38,39. 
Mitochondrial RTG response is the signaling pathway from mitochondria to the nucleus 
triggered by the functional states of mitochondria 40–42. Fig. 2-1 summarizes the regulatory 
mechanism of retrograde response. This pathway maintains a continuous supply of 2-
oxoglutarate, a precursor of glutamate and glutamine biosynthesis, by activating anaplerotic 
metabolism of citrate and oxaloacetate via glyoxylate cycle when respiratory metabolism 
through the TCA cycle is compromised in the event of reduced mitochondrial functions. It is 
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thus one of the important signaling pathways that ensure a continuous supply of precursors, 
such as 2-oxoglutarate for biosynthetic reactions through alternative metabolic pathways.  
Rtg1 and Rtg3 form heterodimers and translocate from the cytoplasm to the nucleus when 
RTG response is activated 43. This translocation depends on the phosphorylation state of Rtg3 
and the transcriptional activation domain is contained within Rtg3. Rtg1/Rtg3 complex binds 
to an R-box (GTCAC) which differs from the canonical E-box site (CANNTG) to which most 
other bHLH proteins bind 44. Among Rtg1/Rtg3 target genes are several TCA cycle genes, but 
the prototypical target is CIT2 42 which encodes a peroxisomal citrate synthase in S. cerevisiae. 
In petite cells (cells that contain nonfunctional, mutated mtDNA (ρ–) or have completely lost 
their mtDNA (ρ0)), the transcripts encoding TCA cycle and glycolytic enzymes were found to 
be increased under repressing (i.e., glucose) and derepressing (i.e., raffinose) growth conditions 
45, while stimulation of glycolysis was also observed in ρ– cell when grown under glucose 
condition, with increased glycerol synthesis and decreased trehalose production 46. 
 
Fig. 2-1. Retrograde regulation in yeast, induced by Rtg1 and Rtg3 complex. Rtg1/Rtg3 is, in turn, 
regulated by another repressor protein Mks1, whose association with Bmh1/Bmh2 prevents 
translocation of Rtg1/Rtg3 from the cytoplasm to the nucleus. A phosphatase Rtg2, acts upstream, 
dephosphorylates and binds to Mks1 to allow retrograde response (adapted from Butow and Avadhani, 
2004 41). 
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In addition, the target of rapamycin (TOR) kinase pathway, an essential pathway that 
controls multiple cellular processes in response to nutritional signals, was shown to negatively 
regulate RTG target genes 47–49. Glutamate, glutamine and proline were reported as signaling 
molecules and both TOR-dependent and TOR-independent modes for RTG target gene 
expression have been demonstrated 47,50,51. The interplay between TOR and RTG pathways, as 
well as the heterodimeric nature of Rtg1/Rtg3 regulators suggest that more complex metabolic 
regulations exist corresponding to various nutrition and growth conditions. In particular, 
metabolic signals that regulate TOR and RTG target genes are only partly understood, and it is 
unclear if the metabolites themselves are regulated by these pathways. In a recent study by 
Zhang et al. (2013) 52, adenosine triphosphate (ATP) was identified as a candidate signaling 
molecule in the mitochondrial retrograde pathway. However, the association of other 
metabolites are unknown, and there is a possibility of other metabolic signals since RTG 
pathway functions to recover the metabolic balance when TCA cycle is repressed. Therefore, 
characterization of metabolite pools would represent the first screening step to identify these 
metabolic signals. 
In this chapter, metabolomics approach is applied to find metabolic regulations possibly 
mediated by Rtg1 and Rtg3. While RTG gene deletion exhibited no difference in growth rates 
when grown in synthetic complete media, a significant alteration in metabolic pathways, 
especially those involving polyamine biosynthesis, as well as TCA and glyoxylate cycles was 
observed. It was found that metabolic alterations occur at various metabolic sites, and that these 
changes relate to different growth phases, but the difference can be detected even at mid-
exponential phase. This study illustrates a broader assessment of metabolic change following 
RTG-gene deletion than previously described. 
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2.2. Experimental section 
2.2.1. Strain growth conditions and sample preparation  
Yeast BY4742 (MATα leu2∆0 lys2∆0 ura3∆0 his3∆1) was used as the parental/wild-type 
strain for all experiments. BY4742 isogenic derivatives, rtg1∆ disruptant (MATα leu2∆0 lys2∆0 
ura3∆0 his3∆1 rtg1::kanMX) and rtg3∆ disruptant (MATα leu2∆0 lys2∆0 ura3∆0 his3∆1 
rtg3::kanMX), were purchased from Open Biosystems (Huntsville, AL, USA). All cultures were 
grown in synthetic media composed of 0.67% Difco™ yeast nitrogen base without amino acids 
(BD, MD, USA), 2% glucose (Nacalai Tesque, Kyoto, Japan) and standard concentrations of 
amino acids and bases 53. The cultivation and sampling were performed as follows. Yeast cells 
from frozen glycerol stock were plated onto YPD agar plates (10 g/L yeast extract, 20 g/L 
peptone, 20 g/L glucose, 20 g/L agar (all from BD, MD, USA except glucose and agar from 
Nacalai Tesque), with added geneticin G418 (Wako, Osaka, Japan) 200 µg/mL for disruptant 
strains) and grown at 30 °C for 2 days. After two days, a single colony was obtained, transferred 
to liquid media and let to grow overnight (pre-culture) at 30 °C in a rotary shaker (200 rpm). A 
portion of the pre-cultured yeast cells were then transferred to fresh media, starting optical 
density at 600 nm (OD600) of 0.1, and continued to grow at 30 °C to desired OD600 and harvested 
using a rapid filtration system. The harvested cell amount was kept at 5 OD units, equivalent to 
1 mg of cells by dry weight at each sampling point. After washing with 5 mL water, the filter-
bound cells were inserted into 1 mL of −30 °C precooled single-phase extraction solvent 
(methanol/chloroform/water = 5/2/2 v/v/v %) with added 1.2 µg/mL of 1,4-
piperazinediethanesulfonic acid, PIPES (Dojindo, Kumamoto, Japan) as an internal standard and 
immediately quenched in liquid nitrogen. The samples were kept at −80 °C until extraction. 
Extraction was carried out at 4 °C, 1200 rpm for 30 min. After that, all liquid extract was 
transferred to a new tube, 400 µL water added, vortexed and centrifuged at 4 °C, 16100 rcf 
(relative centrifugal force) for 3 min to separate polar and non-polar phases. The upper polar 
phase was collected, concentrated five times from the initial volume and ready for LC-MS 
analysis. Extracted samples were analyzed within 24 h after extraction.  
For extracellular metabolome, ~1 mL of the medium filtrate was collected at the same time 
during cell filtration and diluted four times with water prior to LC-MS analysis. 
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2.2.2. Metabolite profiling and quantification  
The analysis platform consists of a Shimadzu Nexera series UHPLC system (Shimadzu, 
Kyoto, Japan) coupled to a triple quadrupole mass spectrometer, LCMS-8030, with a 
modification to improve the sensitivity (Shimadzu, Kyoto, Japan). Two LC/MS methods were 
employed; (1) ion-pairing reversed phase ultrahigh performance liquid chromatography-
tandem mass spectrometry (UHPLC-MS/MS) to detect mainly anionic metabolites, such as 
sugar phosphates and nucleotides from primary metabolism; and (2) regular reversed phase 
UHPLC-MS/MS for the analysis of other metabolites undetected in ESI negative mode. For 
ion-pairing UHPLC-MS/MS, the method was developed based on Luo et al. (2007) 29 and 
Buescher et al. (2010) 31, modified to match in-house LC and MS system and tested with several 
types of columns and analytical parameters to optimize peak shape and separation profile. The 
MS/MS fragment for each analyte was determined using authentic standards. In addition, the 
analysis time was successfully accelerated from 36 min 31 to 15 min. The final analytical 
conditions were as follows; column: L-Column2 ODS (150 mm x 2.1 mm, 3 µm, Chemicals 
Evaluation and Research Institute Japan); flow rate: 0.3 mL/min; column temperature: 35 °C; 
mobile phase A: water containing 10 mM tributyl amine and 15 mM acetic acid; mobile phase 
B: methanol; gradient program: 0% B (0-0.5 min) - 25% B (7.5 min) - 90% B (11-11.5 min) - 
0% B (11.6-15 min); sample cycle time: 15 min; injection volume: 3 µL. The mass 
spectrometric parameters were: ESI negative mode; desolvation line (DL) temperature: 250 °C; 
nebulizer gas flow: 2 L/min; heat block temperature: 400 °C; other parameters were optimized 
automatically by flow injection analysis and auto-tuning.  
For regular reversed phase UHPLC-MS/MS, the parameters were as follows: column: 
Discovery HS F5-3 (150 mm × 2.1 mm, 3 µm, Supelco Analytical, PA, USA); flow rate: 0.3 
mL/min; column temperature: 40 °C; mobile phase A: water with 0.1% formic acid; mobile 
phase B: acetonitrile with 0.1% formic acid; gradient program: 0% B (0-1 min) - 20% B (11 min) 
- 100% B (11.5-13 min) - 0% B (13.1-15 min); sample cycle time: 15 min; injection volume: 3 
µL. The mass spectrometric parameters were: ESI positive mode; desolvation line (DL) 
temperature: 250 °C; nebulizer gas flow: 2 L/min; heat block temperature: 400 °C; other 
parameters were optimized automatically by flow injection analysis and auto-tuning. The 
optimized multiple reaction monitoring (MRM) parameters and retention time for each 
metabolite are listed in Supplementary Table S1. 
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All samples were kept in a 4 °C autosampler during analysis. Standard mixtures of authentic 
metabolites and the pooled QC sample 54,55 were injected periodically throughout the analysis 
run for evaluating the stability and reproducibility of the analytical system. All reagents were 
of LC-MS grades (Wako, Osaka, Japan). 
Peak picking was conducted by LabSolutions (Shimadzu, Kyoto, Japan) followed by 
manual inspection. The parameters were set as follows: integration: auto, max peak: 3, width: 
5 s; smoothing: standard, counts: 5, width: 1 s; identification: absolute RT and closest peak, 
target window: 5%, reference window: 5%, process time: ±1 min. Obtained peaks were 
identified based on an in-house metabolite library. The identity was checked by spiking 
authentic standards to yeast extract and confirming that the particular metabolite peak intensity 
increases with added concentration. Pooled yeast aliquots were used as a quality control for 
reproducibility monitoring 54,56. Peaks with poor reproducibility (relative standard deviation, 
RSD of peak intensity >30% 55) were omitted from the list. 
 
2.2.3. Multivariate data analysis 
The amount of each metabolite (peak intensity) was normalized to internal standard 1,4-
piperazinediethanesulfonic acid (PIPES), mean-centered and scaled to unit variance. Principal 
component analysis (PCA) was performed using SIMCA-P+ ver13 (Umetrics, Umeå, Sweden). 
Pathway analysis was performed using MetaboAnalyst 2.0 57. Heat map and hierarchical 
clustering of fold-change normalized intensities were performed on Cluster 3.0 58 and viewed 
on Java Treeview 59. The statistical difference (two-tailed heteroscedastic t-test) was calculated 
using MS Excel. Pathway mapping was performed by VANTED V2.1.0 60. 
 
2.2.4. Yeast chronological lifespan measurement  
The chronological lifespan (CLS) measurement was based on Parella and Longo (2008) 61. 
Briefly, aliquots of yeast culture grown to the stationary phase were diluted to approximately 
103–104 cells/mL, and 100 µL were spread onto YPD (1% yeast extract, 2% peptone, 2% 
dextrose, 2% agar (% w/v)) plates. Yeast colonies were counted after 2–4 days of incubation at 
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30 °C. CLS (at Day X) is defined as the percentage of the number of colonies at Day X divided 
by the number of colonies at Day 3.  
 
2.3. Results and discussion 
2.3.1. Time-course metabolic profiling of RTG-deleted strains 
Wild-type BY4742 and RTG-deletion strains showed a comparable growth under SC 
medium (maximum specific growth rate, µ = 0.456±0.011 h-1, 0.461±0.015 h-1 and 0.462±0.013 
h-1 for BY4742, rtg1∆ disruptant and rtg3∆ disruptant respectively). Since RTG response is 
initiated under decreased mitochondrial and respiratory function, it is expected that declined 
growth resulting from nutrient cessation and stress accumulation in the stationary growth phase 
would yield sufficient metabolomics pattern which can distinguish between wild-type and 
strains lacking RTG response. Therefore, it is appropriate that the metabolic profiling is 
performed at stationary phase. However, such response against stress or growth adjustment can 
also be sensed at metabolite levels sooner before there is a detectable change in phenotype, such 
as demonstrated previously in yeast replicative lifespan study 62. Therefore, a time-course 
metabolic profiling should be designed so that the difference between wild-type and rtg1∆ 
disruptant, or rtg3∆ disruptant can be captured as early as possible.  
The yeast strains grown to stationary phase were sampled at four sampling points. The 
culture was started at OD600=0.1 (0 h). Each sampling point was taken at various times with 
different optical density values, OD600, corresponding to different growth phases (OD600=1 at 5 
h for mid-exponential, OD600=5 at 9 h for late-exponential, OD600=10 at 26 h for post-diauxic 
and at 76 h for stationary phases). The collected culture volume was adjusted according to the 
OD value so that the total cell number for metabolomics profiling is kept constant 
(approximately 5 x 107 cells for each sample). Under high glucose condition, initially, S. 
cerevisiae operates mainly in the glycolytic mode to ferment glucose to ethanol independent of 
the presence of oxygen. During this stage, the expression of the genes encoding TCA cycle 
enzymes and other genes required for growth under non-fermentable carbon sources is 
repressed, a phenomenon known as glucose repression. Mitochondrial function is also repressed. 
Along with decreased glucose concentration, cells switch to gluconeogenesis and increase their 
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respiratory rate and, finally, enter the stationary phase, where they accumulate storage 
carbohydrates. Therefore, the sampling points cover different metabolic states of the cells. 
Additionally, extracellular metabolites from the growth medium were also measured. 
As a result, 96 intracellular metabolites from yeast cell extracts and 53 extracellular 
metabolites from the growth medium were identified. The metabolite peaks were normalized 
to an internal standard 1,4-piperazinediethanesulfonic acid (PIPES), mean-centered and scaled 
to unit variance before subjected to data analysis.  
First, to reveal metabolic alteration patterns between RTG disruptants and wild-type strains, 
principal component analysis (PCA) was performed. PCA is an unsupervised multivariate 
analysis that seeks the variance among different groups of samples and plots them so that the 
largest variance is contained in the first principal component, the second largest variance in the 
second principal component, and so on. Metabolome data (intracellular metabolites) were fitted 
into PCA with five significant components (Supplementary Table S2). PCA score plot (Fig. 2-
2 (A)) shows that the first principal component (PC1, accounting for 53.7% of the total 
variance), separates between different growth phases, while principal component 2 (PC2, 
accounting for 13.5% of the total variance), separates between wild-type and mutant strains. 
This result indicated that gene deletion effects can be observed at metabolite levels with high 
resolution, even when there is no observable change in growth rate. 
Next, PCA loading plot (Fig. 2-2 (B)) was examined, which shows metabolites that 
contribute to the separation observed on the score plot (for a complete list of loading values, 
see Supplementary Table S3). Along PC1, nucleotide monophosphates and ribonucleosides 
were seen as major contributors to discrimination of samples at late growth phases (26 and 76 
h), while proteinogenic amino acids except for proline and cysteine, and glycolysis 
intermediates were generally abundant in samples at early growth phases. Along PC2, increased 
level of 2-oxoglutarate and glyoxylate was distinctive in wild-type at 76 h, while putrescine, 
cAMP, threonine and ornithine were high in RTG-deficient strains.  
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Fig. 2-2. (A) PCA score plot for time-course metabolic profiling at 5 h, 9 h, 26 h and 76 h of control 
strain BY4742, and rtg1∆ and rtg3∆ disruptants (n=3). The metabolites were normalized to an internal 
standard (PIPES) and auto-scaled. Ellipse indicates 95% confidence border based on Hotelling’s T2. 
Separation among different sampling points (different growth phases) can be seen along PC1, while the 
separation between control and disruptant strains was observable on PC2. 
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Fig. 2-2. (B) The corresponding loading plot illustrating metabolites that contribute to the separation on 
PC1 and PC2. Along PC1, nucleotide monophosphates and ribonucleosides were seen as major 
contributors to discrimination of samples at late growth phases (26 and 76 h), while proteinogenic amino 
acids except for proline and cysteine, and glycolysis intermediates were generally abundant in samples 
at early growth phases. Along PC2, increased level of 2-oxoglutarate and glyoxylate was distinctive in 
wild-type BY4742 at 76 h, while putrescine, cAMP, threonine and ornithine were high in RTG-deficient 
strains. For the complete list of loading values, see Supplementary Table S3. 
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2.3.2. Metabolites and metabolic pathways associated with RTG1 and RTG3 
The purpose of PCA is to observe the separation pattern between wild-type and RTG-
deletion strains. As the separation was successfully observed on the second principal 
component, the metabolites that showed a large loading value on PC2 were further analyzed. 
The loadings describe the multivariate makeup as a vector in multivariate space, and thus 
determine the underlying variables that are important to each PC. The 50 most important 
metabolites, with absolute loading values ≥ 0.05 are shown in Fig. 2-3 (A). High levels of TCA 
and glyoxylate cycle intermediates (2-oxoglutarate, glyoxylate, malate, isocitrate, citrate, 
succinate) positively correlate with RTG-genes (increased in BY4742 and decreased when 
RTG-genes were deleted), while high levels of polyamine biosynthetic intermediates 
(putrescine, ornithine, spermidine) negatively correlate with RTG-genes (increased when RTG-
genes were deleted).  
To get the overall view of the contribution of these metabolites into different metabolic 
pathways, the 50 most influential metabolites were subjected into pathway enrichment analysis 
using MetaboAnalyst 2.0 57. The result is shown in Fig. 2-3 (B) and Table 2-1. Besides TCA 
and glyoxylate cycles, amino acid metabolism makes up the majority of the affected pathways. 
TOR activity is closely related to amino acid signaling, thus the result in part reflects the 
involvement of TOR in RTG pathway. This result also suggests that Rtg1 and Rtg3 may also 
hold regulatory effects on amino acid metabolisms other than glutamate and glutamine. 
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Fig. 2-3. (A) Loading values for 50 most influential metabolites along principal component 2, PC2 that 
distinguishes RTG-deficient strains from control BY4742. Positive loadings indicate a positive 
correlation with RTG regulation (decreased when the RTG regulatory gene was deleted), while negative 
loadings indicate a negative correlation with RTG regulation (increased when the RTG regulatory gene 
was deleted). (B) Overview of pathway analysis, showing matched pathways according to pathway 
enrichment analysis and pathway impact values from pathway topology analysis. Circles represent the 
metabolite-matched pathways of S. cerevisiae retrieved from Kyoto Encyclopedia of Genes and 
Genomes (KEGG). Color intensity indicates the significance of the pathway (the darker the more 
significant), while size indicates pathway impact score (the centrality of its involved metabolites). 
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Table 2-1. Pathway analysis using MetaboAnalyst 2.0 (hits ≥ 2, arranged according to p-
values). 
Pathway name Total Hits p -log (p) FDR Impact 
Arginine and proline 
metabolism 
37 13 2.37E-08 17.556 1.54E-06 0.57168 
Alanine, aspartate and 
glutamate metabolism 
20 8 5.69E-06 12.077 0.000185 0.87254 
Aminoacyl-tRNA 
biosynthesis 
67 13 4.65E-05 9.9767 0.001007 0 
Glutathione metabolism 23 7 0.000182 8.6137 0.002951 0.63277 
Citrate cycle (TCA cycle) 20 6 0.000608 7.4058 0.006591 0.30939 
Nitrogen metabolism 8 4 0.000608 7.4047 0.006591 0 
Glyoxylate and 
dicarboxylate metabolism 
14 5 0.000747 7.1989 0.00694 0.48551 
Glycine, serine and 
threonine metabolism 
26 6 0.00275 5.8963 0.022342 0.41988 
beta-Alanine metabolism 7 3 0.005565 5.1912 0.040194 1 
Pyrimidine metabolism 35 6 0.012898 4.3507 0.083836 0.25014 
Lysine biosynthesis 19 4 0.020822 3.8717 0.12304 0.125 
Cysteine and methionine 
metabolism 
33 5 0.037927 3.2721 0.20544 0.31009 
Purine metabolism 60 7 0.053069 2.9362 0.26535 0.07859 
Butanoate metabolism 17 3 0.071451 2.6387 0.33174 0.28571 
Cyanoamino acid 
metabolism 
10 2 0.11148 2.1939 0.48308 0 
Valine, leucine and 
isoleucine biosynthesis 
24 3 0.16013 1.8318 0.65052 0.07519 
Sulfur metabolism 13 2 0.17308 1.754 0.66178 0.05319 
Propanoate metabolism 14 2 0.19472 1.6362 0.70314 0 
Pantothenate and CoA 
biosynthesis 
16 2 0.23889 1.4318 0.81724 0 
Starch and sucrose 
metabolism 
18 2 0.28357 1.2603 0.92162 0.15497 
Porphyrin and chlorophyll 
metabolism 
20 2 0.32811 1.1144 1 0 
Pyruvate metabolism 23 2 0.39349 0.93271 1 0.1159 
 
31 
 
Since the highest positive and negative loading was observed in 2-oxoglutarate and 
putrescine respectively, the regulatory effects of Rtg1/Rtg3 on TCA/glyoxylate cycle and 
superpathway of polyamine biosynthesis were further investigated. Time-course profiles of 
metabolites from TCA/glyoxylate cycle and polyamine biosynthesis are shown in Fig. 2-4. As 
expected, citrate levels were reduced significantly in RTG disruptant strains, consistent with 
previous studies that reported the transcriptional regulation of CIT2 by the Rtg1/Rtg3 complex 
42. Other metabolic intermediates shared in TCA and glyoxylate cycles (2-oxoglutarate, isocitrate, 
glyoxylate, malate, succinate) were also decreased in the disruptants, especially during 
deceleration/post-diauxic and stationary phases (Fig. 2-4 (A)). Fumarate, which is exclusive to 
the TCA cycle, showed no significant difference. These observations can be explained 
according to the different growth phases. Initially, yeast cells were under a fermentative 
(glucose repressing) condition, during which the TCA cycle and mitochondrial biogenesis are 
repressed 63. As glucose concentration decreases, the cells prepare for the reversion of metabolic 
fluxes; reducing glycolytic activity and increasing the flux thorough the glyoxylate cycle and 
gluconeogenesis 64. Glucose exhaustion leads to a transient diauxic phase, which induces gene 
transcription for mitochondrial proteins and adaptation to respiratory metabolism 65. The low levels 
of TCA/glyoxylate cycle intermediates in RTG deletion mutants after the post-diauxic phase 
thus reflect the inability of the cells to supply anaplerotic citrate from the glyoxylate cycle, 
since the expression of CIT2 requires Rtg1/Rtg3. Interestingly, 2-oxoglutarate readily showed 
a significant decrease from the mid-exponential phase (OD600 = 1), in contrast to other 
TCA/glyoxylate cycle intermediates which only showed clear differences after the post-diauxic 
phase (Fig. 2-4 (A)). 
Another interesting and unexpected observation was the elevated levels of polyamines 
putrescine and spermidine in rtg1∆ and rtg3∆ disruptant strains at stationary phase (the 
intensities of spermine from yeast extract were too low and could not be measured reliably, Fig. 
2-4 (B)). Polyamine compounds have been associated with cytoprotective effects against 
oxidative and inflammatory stresses and its depletion has been linked to yeast aging and 
necrosis 66,67. However, other stress response-related metabolites such as glutathione and 
trehalose showed an opposite trend (Loading plot Fig. 2-2 (B) and Fig. 2-3 (A)). It is possible 
that polyamines might serve as defense metabolites against stresses when RTG pathway is 
inactivated.  
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Fig. 2-4. Legend in the following page. 
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Fig. 2-4. Time-course metabolic profiles of wild-type BY4742, rtg1∆ disruptant and rtg3∆ disruptant 
(n=3) in (A) TCA/glyoxylate cycle and (B) superpathway of polyamine biosynthesis, shown together 
with the neighboring metabolic pathways (PPP: pentose phosphate pathway). Metabolite intensities 
were normalized to an internal standard and relative to those of control (BY4742) at time 5 h (OD600=1). 
In S. cerevisiae, TCA cycle occurs in the mitochondria, while glyoxylate cycle in the peroxisome, 
however both are drawn combined in this figure since only bulk metabolites were measured. Note that 
in the event of fermentative metabolism and glyoxylate cycle activation, the flow from succinate to 
oxaloacetate is blocked (explaining the decreased levels of fumarate which cannot be supplemented 
through the anaplerotic pathway). 
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2.3.3. Metabolic alteration levels in rtg1∆ and rtg3∆ disruptants 
Since Rtg1 and Rtg3 act in a heterodimer complex, and neither protein alone is able to bind 
to R-box sites 44, it is anticipated that the deletion of either gene would result in a similar 
metabolic alteration. Fig. 2-5 depicts a heat map of metabolite changes of BY4742, rtg1∆ and 
rtg3∆ disruptants at four different culture time, corresponding to different growth phases. Both 
rtg1∆ and rtg3∆ disruptants displayed a strikingly similar metabolic alteration pattern. In 
addition, fold-change values were calculated and the statistical difference between the two 
deletion strains was compared (Table 2-2). The fold-change values range from approximately 
-37 times (citrulline in rtg3∆ disruptant at 5 h) to 21 times (spermidine in rtg3∆ disruptants at 
76 h). Only ornithine showed a significant difference between rtg1∆ and rtg3∆ disruptants at 5 
h, while for the rest of the metabolites, rtg1∆ and rtg3∆ disruptants did not differ statistically 
across all time points. Therefore, it is concluded that the deletion of either RTG1 or RTG3 yields 
the same metabolic rearrangements, and the absence of either one component is sufficient for a 
shortfall of RTG response. However, for a majority of metabolites, RTG3 appears to have more 
profound effects on metabolomics parameters (larger fold-change) upon deletion than RTG1. 
This result was reflected in the PCA score plot (Fig. 2-2 (A)) where rtg1∆ disruptant was 
positioned closer to BY4742 than rtg3∆ disruptant. 
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Fig. 2-5. Heat map showing the differential expression in BY4742, rtg1∆ and rtg3∆ disruptants at four 
different time points. Metabolite intensities were normalized to internal standard and relative to those 
of wild-type BY4742 at time 5 h (OD600=1), averaged and log2 transformed. Metabolite clustering was 
based on Pearson’s correlation and average linkage.  
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Table 2-2. Metabolite fold-change for 50 most important metabolites for rtg1∆ and rtg3∆ disruptants relative to wild-type strain BY4742 at each 
sampling time (-inversed in the case of down-regulation). Bold values indicate statistically significant difference between rtg1∆ and rtg3∆ disruptants 
(p < 0.05, determined by two-tailed heteroscedastic t-test and corrected for multiple testing (Benjamini & Hochberg false discovery rate, FDR)).  
Metabolites 
5 h 9 h 26 h 76 h 
rtg1∆ rtg3∆ p rtg1∆ rtg3∆ p rtg1∆ rtg3∆ p rtg1∆ rtg3∆ p 
TCA/glyoxylate cycle 
2-Oxoglutarate -9.26 -15.92 0.179 -8.32 -9.48 0.682 -3.79 -5.07 0.205 -4.54 -6.28 0.356 
Malate -1.23 -1.51 0.308 -1.14 -1.01 0.647 -1.69 -1.76 0.434 -2.45 -2.68 0.273 
Isocitrate -3.47 -3.89 0.679 -1.17 -1.55 0.721 -5.15 -7.50 0.200 -5.94 -10.86 0.264 
Citrate -1.69 -2.73 0.363 -1.37 -1.51 0.686 -2.11 -4.42 0.206 -2.35 -3.31 0.306 
Succinate 1.09 -1.25 0.358 -1.20 -1.21 0.980 -1.16 -1.19 0.830 -1.97 -2.11 0.530 
Fumarate -1.23 -1.35 0.377 -1.10 -1.16 0.699 1.29 1.12 0.351 -1.34 -1.94 0.304 
Glyoxylate 1.09 -1.39 0.352 -1.21 -1.26 0.620 -1.77 -1.75 0.981 -6.40 -6.00 0.792 
Glycolate -1.20 -1.22 0.885 -1.31 -1.23 0.665 -1.23 -1.06 0.236 -5.50 -6.52 0.376 
Starch and sucrose metabolism 
UDP-glucose -1.15 -1.46 0.377 -1.20 -1.34 0.719 -1.21 -1.56 0.332 -1.25 -1.50 0.330 
Trehalose -1.08 -1.11 0.680 1.17 1.07 0.537 1.29 1.04 0.303 -2.23 -2.70 0.362 
Pyrimidine metabolism 
Orotate -1.40 -2.21 0.341 -1.25 -1.39 0.668 1.05 1.01 0.622 -1.08 -1.15 0.733 
Uridine -1.48 1.18 0.385 1.31 1.96 0.659 -1.24 -1.26 0.987 -1.03 -1.05 0.907 
Thymidine -1.19 1.03 0.376 -1.02 1.03 0.954 1.26 1.26 0.982 -1.26 -1.32 0.802 
CTP -1.27 -1.55 0.363 -1.34 -1.36 0.953 -1.84 -3.12 0.214 -3.51 -4.69 0.341 
UMP -1.28 -1.72 0.398 -1.44 -1.37 0.819 1.26 1.60 0.333 2.12 1.78 0.336 
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CMP -1.17 -1.23 0.867 -1.25 -1.25 0.999 1.71 1.77 0.831 2.25 2.16 0.808 
Purine metabolism 
Xanthine -1.08 1.58 0.374 -1.08 1.14 0.646 -1.24 -1.51 0.217 -1.92 -2.65 0.376 
ATP -1.14 -1.33 0.385 -1.24 -1.37 0.660 -1.38 -2.64 0.196 -2.31 -3.81 0.298 
Deoxyadenosine -1.57 -1.77 0.589 -1.04 1.10 0.675 1.24 1.36 0.325 -1.28 -1.17 0.434 
GMP -1.15 -1.82 0.390 -1.06 -1.05 0.938 1.41 1.95 0.232 2.64 2.34 0.522 
cAMP -1.02 1.03 0.864 1.20 1.29 0.787 1.01 1.63 0.287 4.27 4.43 0.800 
Amino acid metabolism 
Histidine metabolism 
Histidine -1.18 -1.34 0.339 -1.30 -1.50 0.586 -2.52 -2.46 0.851 -2.62 -2.24 0.264 
Cysteine and methionine metabolism 
Cysteine -1.50 -2.62 0.210 -1.11 1.07 0.570 1.17 1.03 0.505 -3.34 -3.58 0.800 
Methionine -1.11 -1.34 0.312 1.26 1.14 0.651 1.03 1.16 0.228 3.87 4.03 0.539 
S-Adenosylmethionine 1.15 1.02 0.840 2.40 2.29 0.924 1.33 2.12 0.212 -1.62 1.08 0.352 
Valine, leucine and isoleucine metabolism 
2-Isopropylmalate -1.54 -2.13 0.377 -2.07 -2.48 0.735 -1.37 -1.66 0.380 -1.64 -1.87 0.434 
Valine -1.28 -1.58 0.235 -1.24 -1.36 0.795 -1.09 1.00 0.281 -1.26 -1.24 0.797 
Lysine metabolism 
Amino adipic acid -5.14 -11.67 0.369 -12.36 -14.42 0.644 -2.47 -3.68 0.190 -5.15 -7.05 0.339 
Glycine, serine and threonine metabolism 
Glycine -1.24 -1.64 0.354 -1.26 -1.18 0.812 -1.31 -1.25 0.835 -1.32 -1.36 0.588 
Glycerate -1.09 -1.23 0.547 -1.15 -1.19 0.936 -1.13 -1.01 0.340 -1.50 -1.85 0.288 
Homoserine 1.31 -1.05 0.342 1.08 1.36 0.687 1.09 -1.10 0.323 1.17 -1.16 0.320 
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Threonine 1.18 -1.02 0.345 1.49 1.60 0.740 1.85 1.77 0.248 1.79 1.56 0.285 
Beta-alanine metabolism 
b-Alanine 1.34 -1.17 0.384 -1.30 -2.01 0.673 1.07 1.26 0.836 -2.98 -2.72 0.798 
Arginine and proline metabolism 
Arginine 1.09 -1.04 0.395 -1.41 -1.51 0.868 -1.43 -1.69 0.307 -2.00 -2.53 0.330 
Citrulline -35.03 -37.33 0.842 -12.89 -10.94 0.669 -3.39 -5.10 0.209 -3.48 -4.42 0.595 
Hydroxyproline -1.06 -1.61 0.090 -1.05 1.02 0.938 -1.08 -1.46 0.325 -1.69 -1.15 0.264 
4-Aminobutyrate -4.65 -5.55 0.689 -1.76 -1.37 0.678 -2.28 -1.48 0.232 1.14 -1.05 0.636 
Proline -1.34 -1.45 0.817 -1.42 -1.25 0.682 -1.17 1.08 0.215 2.91 3.78 0.302 
Alanine, aspartate and glutamate metabolism 
Glutamine -2.01 -2.53 0.306 -2.25 -2.62 0.718 -2.02 -2.61 0.328 -1.93 -2.84 0.340 
Glutamate -2.04 -2.76 0.369 -2.27 -2.63 0.189 -1.57 -1.93 0.237 -1.94 -2.19 0.266 
Aspartate 1.27 1.13 0.387 1.13 1.16 0.678 1.01 -1.20 0.179 1.41 1.16 0.286 
Alanine -1.05 -1.23 0.355 1.08 1.07 0.989 1.21 1.22 0.967 1.86 1.71 0.286 
Phenylalanine, tyrosine and tryptophan metabolism 
Tryptophan -1.11 -1.26 0.336 -1.08 -1.14 0.714 1.38 1.56 0.218 1.79 1.97 0.275 
Glutathione metabolism, polyamine biosynthesis 
Glutathione -1.21 -1.43 0.344 -1.21 -1.27 0.640 -1.03 -1.07 0.272 -1.36 -1.51 0.332 
Spermidine -1.33 -1.74 0.674 -1.12 -1.37 0.675 3.01 3.56 0.641 13.24 20.61 0.383 
Ornithine -1.87 1.13 0.002 1.45 1.81 0.110 -1.15 1.09 0.251 1.90 2.21 0.334 
Putrescine 1.83 2.32 0.343 1.75 2.13 0.723 2.28 1.68 0.324 5.33 4.85 0.732 
Pentose phosphate pathway 
Ribose 5-phosphate -1.41 -2.46 0.341 -1.41 -1.58 0.616 -1.98 -2.06 0.934 -2.67 -2.47 0.651 
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Glycolysis 
Bisphosphoglycerate -1.23 -2.25 0.304 -1.64 -1.62 0.985 -1.92 -2.48 0.522 -3.12 -3.99 0.446 
Others (co-factors) 
NAD -1.20 -1.37 0.328 -1.23 -1.24 0.932 -1.39 -1.51 0.294 -1.29 -1.39 0.343 
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2.3.4. Yeast chronological lifespan and its relation with RTG1 and RTG3 
As described previously, mitochondrial function closely relates to the aging process, and 
therefore, the association between RTG response with aging (lifespan) was further investigated. 
The effect of metabolic rearrangements following RTG response activation/deactivation 
towards aging can be evaluated in terms of yeast chronological lifespan. Activation of the 
mitochondrial RTG pathway has been reported to contribute to genome stability 68 and increase 
the yeast chronological lifespan, CLS 69. In a separate study, decreased TOR signaling was also 
shown to extend CLS 70. CLS is the period of time in which cells remain viable in a non-dividing 
state after nutrients cease in stationary phase 71, often expressed as the number of colonies 
recovered when the yeast cells are transferred back to growth allowing environment.  
In this study, the CLS of rtg1∆ and rtg3∆ disruptants was measured (Fig. 2-6) and indeed, 
CLS was shortened in these strains. Although metabolic parameters showed that RTG3 deletion 
imposed a greater effect than RTG1, CLS between rtg1∆ and rtg3∆ disruptants did not seem to 
differ. Together with metabolome data (Table 2-2), several observations can be made. 
Trehalose and glutathione, two metabolites that have been positively related to stress response, 
were accumulated in BY4742 at stationary phase. Meanwhile, amino acids such as histidine, 
glycine, glutamine, valine, arginine and glutamate were low, while methionine, aspartate, 
alanine, tryptophan, proline and threonine were higher at stationary phase in deletion strains. 
Analysis of growth media (PCA plots of extracellular metabolite from the growth media, 
Supplementary Fig. S1) revealed that extracellular threonine and valine were high in BY4742. 
While the addition of isoleucine, threonine, and valine to growth media was reported to extend 
CLS 72, the effects of intracellular amino acid level were not clarified. 
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Fig. 2-6. The chronological lifespan (CLS) of BY4742, rtg1∆ and rtg3∆ disruptants, measured as the 
number (log %) of viable cells in exhausted growth media after revival on YPD (1% yeast extract, 2% 
peptone, 2% dextrose, 2% agar (% w/v)) plates. CLS at Day 3 (start of the stationary phase) was defined 
as 100%. 
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2.3.5. Comparison with previous literatures 
The enzymatic and metabolic activities in rtg1∆ and rtg2∆ disruptants have been described 
previously by Small et al. (1995) 73. The authors reported that when compared to levels in the 
parental strain, the only changes seen, aside from the absence of peroxisomal citrate synthase, 
were a reduction in mitochondrial citrate synthase activity (~30%–50%), a reduction in acetyl-
coA synthetase activity (~50%), a reduction in cytosolic (NAD) isocitrate dehydrogenase 
activity (~50%) and a reduction in pyruvate carboxylase activity (~50%). These enzymes are 
encoded by the genes, CIT2, CIT1, ACS1/ACS2, IDP2 and PYC1/PYC2, respectively. While 
the reduced citrate and 2-oxoglutarate levels observed in this study might be explained by the 
reduced activity of citrate synthases and isocitrate dehydrogenase, a difference in acetyl-coA 
and oxaloacetate levels between wild-type and RTG disruptants was not observed. However, 
the experiment by Small et al. (1995) 73 was conducted under a non-repressive condition, i.e., 
using raffinose as a carbon source. Moreover, they indicated that the disruptant cells have 
normally respiring mitochondria. In this study, mitochondrial function was confirmed to be 
intact in rtg1∆ and rtg3∆ disruptants, as there were no difference in the cell counts of these 
strains, when grown on YPD (1% yeast extract, 2% peptone, 2% dextrose, 2% agar (% w/v)) 
vs. YPG (1% yeast extract, 2% peptone, 2% glycerol, 2% agar (% w/v)) plates (Supplementary 
Table S4). 
In a recent large-scale microarray transcript profiling by Kemmeren et al. (2014) 22, they 
indicated that there is a marked decrease in CIT1, CIT2, ACO1, IDH1 and IDH2 expressions in 
rtg1∆ and rtg3∆ disruptants. Similar to this experiment, they used BY4742 derivatives and grew 
the yeast strains in synthetic complete (SC) medium with 2% glucose and sampled the cultures 
at the mid-exponential phase. Therefore, the reduced levels of citrate, isocitrate and 2-
oxoglutarate observed in this study might be attributed to the reduced expression of CIT1/CIT2 
(citrate synthases), ACO1 (aconitase) and IDH1/IDH2 (isocitrate dehydrogenases), 
respectively. Moreover, the use of a rich medium does not seem to overcome the lack of 2-
oxogluratarate production in RTG disruptants. Kemmeren et al. (2014) 22 also showed that 
GAP1 and AGP1 were upregulated in rtg1∆ and rtg3∆ disruptants. Gap1 is a general amino 
acid permease that directs the uptake of all naturally occurring amino acids 74,75 and has been 
reported to be regulated by the nitrogen source and amino acid levels 76, while Agp1 is an amino 
acid permease, which transports asparagine and glutamine 77. Chen and Kaiser (2002) 76 showed 
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that high levels of endogenous glutamine and glutamate induced by the deletion of Mks1 (a 
negative regulator of RTG pathway) caused extremely low Gap1 activity. In this study, while 
the endogenous glutamate level was significantly lower in RTG disruptants, the exogenous 
glutamate concentration in the medium for all strains did not differ (Supplementary Figure S2). 
However, reduced levels of both intracellular and extracellular glutamine in RTG disruptants 
can be seen (Supplementary Figure S2). Why increased Gap1 and Agp1 induced by RTG1/RTG3 
deletion seemed to result in an increased uptake of extracellular glutamine, but not glutamate, is 
not clear. Interestingly, two genes that encode glutamate dehydrogenases for the synthesis 
(GDH1) and degradation (GDH2) of glutamate were also increased in RTG disruptants. Gdh1 
synthesizes glutamate from ammonia and 2-oxoglutarate, while Gdh2 degrades glutamate to 
ammonia and 2-oxoglutarate.Taken together, several explanations may underlie these 
observations; (1) there’s a limit on the uptake level of glutamate when it is abundantly present 
in the growth medium; (2) glutamine is preferred over glutamate for an uptake into the cells; 
and (3) 2-oxoglutarate accumulation is primarily governed by de novo synthesis from isocitrate 
by IDH1/IDH2 and not much from glutamate degradation by GDH2.  
Moreover, the characteristic decrease in 2-oxogutarate concentrations in rtg1∆ and rtg3∆ 
disruptants preceding the decrease of other TCA cycle intermediates (citrate, isocitrate, succinate, 
malate) during the mid-exponential growth phase (Fig. 2-4 (A)) suggests that this metabolite 
might play a critical role in controlling the flow and balance of TCA/glyoxylate cycles. Further 
experiments, e.g., a flux analysis using labeled substrates, should be performed to confirm the 
origin of 2-oxoglutarate under sufficient glutamate/glutamine concentrations in the growth 
medium and to investigate the physiological attributions of this metabolite to the metabolic 
reprogramming under RTG deletion. 
 
2.4. Conclusions 
In this chapter, metabolic profiling of rtg1∆ and rtg3∆ disruptant strains was performed. By 
relative comparison of metabolic alteration in these deletion strains with wild-type BY4742, 
metabolites and metabolic pathways associated with RTG1/RTG3 genes and possibly related to 
mitochondrial RTG response were identified. Besides TCA and glyoxylate cycles which have 
been identified previously, other pathways including amino acid metabolism were affected, and 
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thus supporting the idea of multi-regulatory coordination of bHLH proteins in different 
transcription programs. The new insights obtained from this chapter are the markedly reduced 
2-oxoglutarate level which precedes other TCA cycle intermediates, suggesting a key role of 2-
oxoglutarate in balancing TCA/glyoxylate cycle, as well as the elevated levels of polyamines 
at stationary phase in rtg1∆ and rtg3∆ disruptants. In addition, the relationship between RTG-
gene deletion and chronological lifespan (CLS) was confirmed. This study illustrates the power 
of metabolomics in finding gene/transcription factor-metabolite correlations and provides a 
broader assessment of metabolic change following RTG-gene deletion. The outcome of this 
study is expected to lead to deeper investigations into RTG response and bHLH proteins in 
general.  
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Chapter 3 
Global analysis of gene-metabolite correlations in154 
transcription factor deletion strains 
 
3.1. Introduction 
In Chapter 2, the utility of metabolomics approach in TF related study using a representative 
TF complex was demonstrated. In this chapter, I proceeded to perform a global analysis of 
metabolome that covers 154 TF-gene deletion strains.  
As described previously, research in transcriptional regulation involves, among others, the 
determination of DNA-binding domain (DBD) motifs and protein-protein interaction, 
identification of downstream effector genes, quantification of transcript and protein abundances, 
as well as network construction from genome-wide expression data using computational 
methods 16,21,78–80. Despite the huge amount of research, the understanding of global gene 
regulation by transcription factors is not yet complete; in yeast, for about half of the apparent 
sequence-specific DNA-binding TFs, physiological functions and/or DNA-binding sites remain 
unknown 17,81,82. There are also inductions or repressions of pathways that do not seem to be 
the direct target of the TF, which are probably due to transcriptional cascades. For example, 
Hms1, appears to positively regulate genes involved in several diverse pathways, including 
several that have dedicated TFs, and some genes that do not appear to contain Hms1-binding 
sites in their promoters 82. Moreover, while TFs essentially bind to DNA promoter regions to 
initiate their action, transcriptional regulation is not a simple binary on/off control. The number 
of TF molecules also plays a part in determining the level of transcription 83. In addition, one 
TF may be involved in various genes and requires a precise set of protein complex and co-
activators before transcription can be initiated. Furthermore, many regulatory events that link 
triggering cues to final phenotypic reprograming remain poorly characterized, making it 
difficult to predict cellular behavior even when the transcriptional machinery is known. The 
missing link between the change in transcript or protein levels and phenotype (e.g., growth rate, 
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chemical resistance, production of secondary metabolites) has to be investigated. Clearly, an 
alternative approach to studying transcription factors besides gene expression profiling or DNA 
and protein-protein binding is necessary in order to gain an overall picture of gene regulatory 
mechanism. In particular, how perturbation in transcription factors affects metabolite levels and 
ultimately cellular function needs to be addressed.  
So far, studies regarding global transcriptional regulation and/or network using 
metabolomics approach have been limited. Analysis of condition-dependent TF network using 
metabolic flux distribution of 119 yeast TF deletion stains was reported previously 84, which 
reveals that metabolic flux alteration caused by TF deletion occurs almost exclusively at TCA 
cycle, and only 23 strains exhibited differential flux ratio change. Amino acid profiling for 
~5000 yeast single gene deletion strains was also conducted 85, which shows that clustering of 
functionally related genes can be found for arginine biosynthesis and urea cycle pathways but 
not other pathways. However, there are no comprehensive reports on metabolites other than 
amino acids nor a dedicated metabolite profiling for transcription factor deletion strains. 
Although Yeast Metabolome Database (YMDB) 86 serves as a database that lists all the 
metabolites contained in yeast, there are no reports on metabolite levels of specific strain types.  
Metabolomics has been regarded as a high resolution approach, due to its ability to capture 
subtle change in metabolite levels, which often does not manifest in a change in phenotype until 
at a much later stage. For example, Yoshida and colleagues demonstrated that the difference in 
yeast replicative lifespan can be detected from metabolic fingerprints of exponentially growing 
yeast cells (~4 doublings) whereas a conventional method by counting the number of daughter 
cells from a single mother cell requires at least 20 generations before a comparison can be made. 
This finding shows that metabolomics is a powerful tool to uncover a complicated phenotype 
(i.e., lifespan) at earlier stage compared to conventional method. Metabolomics has also been 
used to reveal silent genes, i.e., genes that produce no overt phenotype when deleted from the 
genome, but have distinct metabolic concentrations 87,88. Furthermore, the use of single gene 
knockouts of yeast S. cerevisiae has been proven to be useful in functional genomics studies, 
using transcriptomics and metabolomics approaches 16,84,85,89. Therefore, metabolomics serves 
as an excellent tool to study metabolic phenotype of non-essential gene knockouts of 
transcription factors due to; 1) unlike enzymes, TFs have no one-to-one relation with metabolic 
pathways, and thus hold much more complex regulatory network, and 2) most of these genes 
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are purportedly silent, i.e., the gene deletion does not affect the growth rate of the organism, 
leaving metabolic change as the sole indicator of strain condition. 
In this chapter, the commercially available yeast single gene deletion library was used, and 
metabolite profiling of 154 strains each lacking a non-essential gene putatively encoding 
transcription factor was performed. The strains were then characterized according to their 
metabolic profiles. Core metabolites and co-factors deriving from central metabolic pathways 
such as glycolysis and TCA cycle, as well as amino acids and organic acids that are commonly 
conserved in most organisms were identified. Metabolome dataset can serve as invaluable 
inputs to assist researchers working on transcription factors and yeast biology in general. 
 
3.2. Experimental section 
3.2.1. Strain and culture condition 
All strains used in this study were single gene knockouts from the European Saccharomyces 
Cerevisiae Archive for Functional Analysis (EUROSCARF) 90 collection, with BY4742 (MATα 
leu2∆0 lys2∆0 ura3∆0 his3∆1) as the parental/wild-type strain. The knockout strains were 
purchased from Open Biosystems (Huntsville, AL, USA) which were constructed by replacing 
the target genes with kanMX cassette that confers resistance to geneticin 91. Each experiment 
was conducted with at least three replicates, and BY4742 was used as a control. 
Yeast cells from frozen glycerol stock were plated onto YPD agar plates (10 g/L yeast 
extract, 20 g/L peptone, 20 g/L glucose, 20 g/L agar (all from BD, MD, USA except glucose 
and agar from Nacalai Tesque), with added geneticin G418 (Wako, Osaka, Japan) 200 µg/mL 
for knockout strains) and grown at 30 °C for 2 days. After two days, a single colony was 
obtained and re-streaked on a new YPD plate to increase cell number. This plate was used as a 
master plate for all cultivations. Cultivation was performed in three steps to reduce variation in 
cell growth; pre-pre culture, pre-culture and main culture. All liquid cultures were grown in 
synthetic complete (SC) medium 53. SC was chosen as the growth medium to enable all deletion 
strains to grow comparably without severe growth defect, while still allowing controlled and 
known nutrient composition 85. Preliminary experiment revealed that some of the knockouts 
were auxotroph for certain amino acids. Moreover, minimal medium such as synthetic defined 
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(SD) medium causes severe growth delay in some strains, thus the use of SD medium was not 
feasible. SC medium was prepared as follows: 20 g/L glucose, 6.7 g/L Difco™ yeast nitrogen 
base without amino acids (BD, MD, USA), 1.92 g/L yeast synthetic drop-out media supplement 
without uracil (Sigma-Aldrich, MO, USA), 76 mg/L uracil (Sigma-Aldrich), with geneticin 
G418 added to a final concentration of 200 µg/mL for knockout strains. 
For pre-pre culture, cells were inoculated from the master plate into 3 mL of culture medium, 
followed by incubation at 30 °C in a rotary shaker (200 rpm) for 18 h. Next, for pre-culture, a 
portion of pre-pre-culture broth was diluted into 15 mL fresh culture medium so that the starting 
optical density at 600 nm (OD600) = 0.01, and incubation with shaking was continued for 18 h. 
For main culture, the pre-culture broth was diluted in 15 mL culture medium so that the starting 
OD600 = 0.1, and incubation with shaking was continued until desired optical density values are 
reached. An iMark microplate reader (Bio-Rad, CA, USA) was used to monitor optical density. 
For metabolome sampling, a fast filtration method based on Crutchfield et al. (2010) 92 was 
applied with slight modifications. 5 mL of culture broth at OD600 = 1 (approximately equivalent 
to 5 x 107 cells) were rapidly filtered using a 0.45 µm-pore size, 25 mm-diameter nylon 
membrane (Millipore, MA, USA) under a vacuum filtration. The filter membrane was folded 
and inserted into a 2-mL sampling tube filled with 1 mL single-phase extraction solvent 
(methanol/chloroform/water = 5/2/2 v/v/v %, with 1.2 µg/mL each of 1,4-piperazine 
diethanesulfonic acid (PIPES) and ribitol as internal standards 62) pre-cooled at -30 °C, after 
which the tube was flash frozen in liquid nitrogen and stored at -80 °C until extraction. 
 
3.2.2. Metabolite extraction and sample preparation 
For extraction, the tubes filled with membrane-bound cells and extraction solvent were 
placed in a thermomixer (Eppendorf, Hamburg, Germany) at 4 °C, 1200 rpm for 30 min. After 
that, all liquid extract (900 µL) was transferred to a new tube filled with 400 µL water, vortexed 
and centrifuged at 4 °C, 16100 rcf (relative centrifugal force) for 3 min to separate polar and 
non-polar phases. Next, the upper polar phase was transferred to a new tube via syringe 
filtration (0.2 nm PTFE hydrophilic membrane, Millipore, MA, USA) and divided into two, 
300 µL for LC-MS and 600 µL for GC-MS. The extracts were concentrated five times from the 
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initial volume under a vacuum centrifugation system (VC-96R, Taitec, Japan), transferred to 
glass vials (Chromacol, Hertfordshire, UK) and ready for UHPLC-MS/MS analysis. Samples 
were analyzed within 24 h after extraction. 
For GC/MS samples, concentrated extracts were lyophilized overnight, followed by 
derivatization by oximation and silylation 93. The oximation reagent, methoxyamine 
hydrochloride (Sigma-Aldrich, MO, USA) was first dissolved in pyridine (Wako, Osaka, Japan) 
to a concentration of 20 mg/mL and 75 µL added to each sample tube containing the lyophilized 
extracts. After reaction at 30 °C, 1200 rpm for 90 min, 50 µL of N-methyl-N- 
(trimethylsilyl)trifluoroacetamide (MSTFA) (GL Sciences, Tokyo, Japan) was added and the 
silylation reaction was performed at 37 °C, 1200 rpm for 30 min. The derivatized samples were 
transferred to glass vials (Chromacol, Hertfordshire, UK) and analyzed within 24 h. 
 
3.2.3. LC/MS analysis 
The analysis platform consists of Shimadzu Nexera series UHPLC system (Shimadzu, 
Kyoto, Japan) coupled to a triple quadrupole mass spectrometer, LCMS-8030 with modification 
to improve sensitivity (Shimadzu, Kyoto, Japan). The analytical conditions were as follows; 
column: L-Column2 ODS (150 mm x 2.1 mm, 3 µm, Chemicals Evaluation and Research 
Institute Japan); flow rate: 0.3 mL/min; column temperature: 35 °C; mobile phase A: water 
containing 10 mM tributylamine and 15 mM acetic acid; mobile phase B: methanol; gradient 
program: 0% B (0-0.5 min) - 25% B (7.5 min) - 90% B (11-11.5 min) - 0% B (11.6-15 min); 
sample cycle time: 15 min; injection volume: 3 µL. The mass spectrometric parameters were: 
ESI negative mode; desolvation line (DL) temperature: 250 °C; nebulizer gas flow: 2 L/min; 
heat block temperature: 400 °C; other parameters were optimized automatically by flow 
injection analysis and auto-tuning. The MS/MS fragment for each analyte was determined using 
authentic standards. Multiple reaction monitoring (MRM) transition parameters and retention 
time for each metabolite are listed in Supplementary Table S1. All samples were kept in a 4 °C 
autosampler during analysis. All reagents were of LC-MS grades (Wako, Osaka, Japan). 
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3.2.4. GC/MS analysis 
GC/MS was performed on a GCMS-QP2010 Ultra (Shimadzu, Kyoto, Japan) gas 
chromatograph coupled with a quadrupole mass spectrometer equipped with an AOC-20i/s 
autoinjector (Shimadzu, Kyoto, Japan). A CP-SIL 8 CB Low Bleed/MS column (Varian, CA, 
USA) 30 m × 0.25 mm (0.25 µm) was used for the GC separation. The mass spectrometer was 
auto-tuned and calibrated prior to analysis. 1 µL of sample was injected in split mode with a 
split ratio of 1:25. The inlet temperature was set at 230 °C and the column flow rate was 1.12 
mL/min (linear velocity 39 cm/s). The column temperature was held at 80 °C for 2 min, raised 
by 15 °C/min to 330 °C, and held at 330 °C for 6 min. The transfer line and ion source 
temperatures were 250 °C and 200 °C respectively. Electron ionization (EI) was performed at 
70 eV. The mass range of the detector was set to m/z 85 to 500 and the detector voltage (set by 
auto-tuning) was 0.93 kV. 
An alkane standard mix was prepared from 25 µL each of C8-C20 and C21-C40 alkane 
standard solutions, diluted with an addition of 25 µL pyridine and injected at the start of each 
analytical run for calculating retention indices. In addition, a blank pyridine sample was injected 
every 8 samples for diagnostic purposes (to check for column bleed and carryover). 
 
3.2.5. Metabolite identification and validation procedure 
The stability and reproducibility of the method were evaluated using pooled quality control 
(QC) samples 55,56,94. QC samples were prepared by pooling an equal volume of yeast extracts 
from each sample within the same analytical batch. The same QC aliquot from one injection 
vial was used for each analytical batch, injected at least three times at the start of the analytical 
batch after the system has stabilized, then at every sixth injection throughout the entire 
analytical workflow. Additionally a standard mixture of 1 µM was routinely injected at the 
beginning, middle and end of each analysis run. 
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3.2.6. Dataset construction 
For LC/MS, peak picking was conducted by LabSolutions (Shimadzu, Kyoto, Japan) 
followed by manual inspection. The parameters were set as follows: integration: auto, max 
peak: 3, width: 5 sec; smoothing: standard, counts: 5, width: 1 sec; identification: absolute RT 
& closest peak, target window: 5%, reference window: 5%, process time: ± 1 min. Obtained 
peaks were identified as metabolites contained in yeast extracts by matching the extracted ion 
chromatograms with in-house metabolite library (MS/MS fragment and retention time). The 
identity was checked by spiking authentic standards to yeast extract and confirming that the 
particular metabolite peak intensity increases with an added concentration. To correct for matrix 
effect commonly observed in ESI-based LC/MS, the raw peaks were calibrated using the 
external calibration method. Initially, primary stock solutions from authentic standards were 
prepared in water at a concentration of 10-100 mM for each metabolite, from which standard 
mixtures of various concentrations were made. Standard mixtures were spiked into yeast 
extracts and used for making calibration curves. For analysis from different batches, the 
calibrated peaks were then multiplied by a correction factor (peak intensity of a standard 
mixture during calibration / peak intensity of a standard mixture during actual run), before 
integrated into one dataset. 
For GC/MS, raw data files were converted into netCDF (*.cdf) format according to the 
ANDI (Analytical Data Interchange Protocol) specification using the proprietary software 
GCMSsolution (Shimadzu, Kyoto, Japan) before peak detection, baseline correction and 
retention time alignment using the freely available data processing tool MetAlign 95. Data 
matrices from the alignment were then imported into AIoutput2 ver.1.29 96 for an automated 
retention indices (RI)-based target compound identification and quantification. 
 
3.2.7. Multivariate data analysis 
Principal component analysis (PCA) was performed using SIMCA-P+ ver13 (Umetrics, 
Umeå, Sweden). Heat map and hierarchical clustering of fold-change normalized intensities 
were performed on Cluster 3.0 58 and viewed on Java Treeview 59. Statistical difference (two-
tailed heteroscedastic t-test) was calculated using MS Excel. 
52 
 
 
3.3. Results and discussion 
3.3.1. Metabolites identification and quantification 
In this study, due to the large number of strains, cultivation and analysis steps were 
performed in four batches and included wild-type strain BY4742 as control in each batch. 
Supplementary Table S5 lists all the strains used in this study, the maximum specific growth 
rate, and the adenylate energy charge (EC). EC indicates the energy status of the cells, where 
exponentially growing cells have an EC of ~0.8 while an EC of <0.5 is indicative of dead cells 
97. Growth rates serve as a general measure of the effects of gene deletion. Wild-type strain 
BY4742 grew at a maximum specific growth rate of 0.45-0.48 h-1. All deletion strains grew 
well in SC medium except for six knockout strains (ino2∆ disruptant, ino4∆ disruptant, opi1∆ 
disruptant, gcr2∆ disruptant, aft1∆ disruptant, ada2∆ disruptant) that exhibited a growth defect 
of > 20% compared to wild-type. 
In microbial metabolome experiments, it is important to ensure that metabolites are rapidly 
quenched at the time of sampling. A fast filtration method followed by subsequently dipping 
the cells into cold extraction solvent 92 was used, which usually takes ~30 s from taking out 
samples from liquid culture to quenching. Adenylate energy charge, EC, calculated as ([ATP] 
+ 0.5[ADP])/([AMP] + [ADP] + [ATP]), was in the range of 0.72 to 0.88 (Supplementary Table 
S5), which is typical of exponentially growing cells 28,97,98, suggesting that quenching was 
sufficient. 
A total of 84 metabolites were successfully identified and quantified from LC/MS and 
GC/MS (Table 3-1). Similar to the previous chapter, selection of metabolites was based on < 
30% of RSD of QC samples 55. The median RSD for Batch 1-4 were 6.6%, 8.1%, 10.9%, 9.5%, 
respectively. 
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Table 3-1. List of metabolites obtained from the metabolic profiling of 154 TF-deletion strains.  
 Amino acids Bases, 
nucleotides 
Sugar and 
derivatives 
Organic acids Others, co-
factors 
LC-
MS 
(67) 
Arginine 
Histidine 
Serine 
Asparagine 
Glutamine 
Homoserine 
Threonine 
Trehalose 
Proline 
Valine 
Methionine 
Isoleucine 
Tyrosine 
Amino adipic 
acid 
Glutamate 
Aspartate 
Phenylalanine 
Pyroglutamate 
Tryptophan 
Glutathione 
Guanine 
Inosine 
Guanosine 
CMP 
UMP 
GMP 
AMP 
cAMP 
CDP 
GDP 
ADP 
CTP 
GTP 
UTP 
ATP 
G6P 
R5P 
S7P 
F6P 
DHAP 
GAP 
Ru5P 
F1P 
UDP-Glu 
F2,6P 
F1,6P 
1,3-BPG 
α-
Glycerophosphate 
(Glycerol 3P) 
Nicotinate 
Pantothenate 
Succinate 
Fumarate 
Oxalacetate 
Malate 
2-Oxoglutarate 
Isocitrate 
Citrate 
PEP 
2-
Isopropylmalate 
Orotate 
Pyruvate 
Acetyl CoA 
NAD 
NADP 
FMN 
FAD 
NADPH 
GC-
MS 
(17) 
Alanine 
Glycine 
Leucine 
Lysine 
Cysteine+Cystine 
Citrulline 
Uracil 
Adenine 
Inositol 
Glycerol 
Glucose 
β-Lactose 
Melibiose 
 2-Aminoethanol 
Urea 
Phosphate 
Octadecanoate 
(Stearic acid) 
Abbreviations: G6P: glucose 6-phosphate; R5P: ribose 5-phosphate; S7P: sedoheptulose 7-phosphate; F6P: 
fructose 6-phosphate; DHAP: dihydroxyacetone phosphate; GAP: glyceraldehyde 3-phosphate; Ru5P: 
ribulose 5-phosphate; F1P: fructose 1-phosphate; UDP-Glu: uridine diphosphate-glucose; F2,6P: fructose 
2,6-bisphosphate; F1,6P: fructose 1,6-bisphosphate; 1,3-BPG: 1,3 bisphosphoglycerate; PEP: 
phosphoenolpyruvate; NAD: nicotinamide adenine dinucleotide; NADP: nicotinamide adenine dinucleotide 
phosphate; FMN: flavin mononucleotide; FAD: flavin adenine dinucleotide; NADPH: reduced 
nicotinamide adenine dinucleotide phosphate; ATP: adenosine 5’-triphosphate; ADP: adenosine 5’-
diphosphate; AMP: adenosine 5’-monophosphate; GTP: guanosine 5’-triphosphate; GDP: guanosine 5’-
diphosphate; GMP: guanosine 5’-monophosphate; CTP: cytidine 5’-triphosphate; CDP: cytidine 5’-
diphosphate; UMP: uridine 5’-monophosphate; cAMP: adenosine 3',5'-cyclic monophosphate. 
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3.3.2. Validation of analytical performance and data normalization 
Medium- to large- scale metabolomics studies often suffer from batch-to-batch 
reproducibility problem. To demonstrate the degree of batch-to-batch variation, first only wild-
type BY4742 strains were plotted in PCA (Fig. 3-1). It was found that normalization to an 
internal standard (calculated as the ratio of the peak intensity of each metabolite to the peak 
intensity of the internal standard) was not sufficient for eliminating batch-to-batch variation. 
The same wild-type strain (BY4742) was used in each batch, thus technically the wild-type 
samples should all be clustered together on PCA. However, from Fig. 3-1, while Batch 1 and 
Batch 3 were clustered together, Batch 2 and 4 were separated, showing that batch-to-batch 
variation is inevitable.  
To further examine this problem, QC samples were used as a benchmark. The use of QC 
samples from pooled test extracts to monitor analytical performance has been demonstrated in 
metabolome studies for urine 56,99 and plasma or serum 100. QC samples prepared from aliquots 
of test samples provide ‘mean’ representative of all the metabolites contained and thus 
considered appropriate for the evaluation of reproducibility and sample stability. It was 
observed that QC samples were clustered together on the PCA plot (Fig. 3-2 (A)), 
demonstrating that the analysis platform is sufficiently stable throughout the run.  
However, in terms of between-batch reproducibility, a clear separation between different 
batches can be seen (Fig. 3-2 (B) and Fig. 3-3 (A)). While ion pairing LC-MS has the advantage 
of wide coverage of metabolites of various species, including polar metabolites from central 
metabolism, with relatively stable retention time 29,31,101, it lacks reproducibility of different 
batch analysis. Peak intensities tend to deteriorate over time, while there is a need for regular 
cleaning due to accumulation of residual ion pairing reagent in the analysis line. As reported 
previously, day-to-day analytical variation was inevitable, accounting for the major portion of 
data variability 55. Therefore, integration of data from different analytical runs and different 
batches needs a thorough consideration and a proper normalization method. It is important to 
minimize these differences so that the true interpretation of biological phenomena can be 
derived, which reflects strain differences instead of batch differences.  
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Fig. 3-1. Batch-to-batch variation observed in wild-type samples BY4742. Data was normalized to 
internal standard and Pareto-scaled (mean-centered and divided by the square root of standard deviation). 
Numbers 1-4 indicate batch number. Ellipse indicates 95% confidence border based on Hotelling’s T2 
statistics. One control sample was identified as an outlier and removed from the dataset. 
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Fig. 3-2. (A) Stability and reproducibility of the analysis method within the same analytical run. The 
peaks were normalized to internal standard and Pareto-scaled. QC samples injected periodically were 
clustered together, showing that the method is stable and reproducible within the same analysis run. 
Data were taken from Batch 1 from ion pairing-LC-MS/MS data. Ellipse indicates 95% confidence 
border based on Hotelling’s T2 statistics. 
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Fig. 3-2. (B) Stability and reproducibility of the analysis method between two separate analytical runs. 
The peaks were normalized to internal standard and Pareto-scaled. When two separate runs were 
combined, batch separation can be observed along PC1, indicating that an alternative normalization 
procedure is necessary. Data were taken from Batch 1 and 2 from ion pairing-LC-MS/MS data. Ellipse 
indicates 95% confidence border based on Hotelling’s T2 statistics. 
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These observations are consistent with a previous study of long-term human serum 
metabolomics which reported that longitudinal variations cannot be easily compensated for 
with internal standards 54. As a solution, a normalization method using wild-type strain as a 
reference was employed. This method is frequently used in microarray analysis (relative 
transcript expression). As a result, the variation was remarkably reduced when normalization 
to wild-type strain (calculated as log2-transformed fold-change, i.e., ratio of metabolite in the 
disruptant strain vs. wild-type) was performed (Fig. 3-3 (B)). For LC/MS, because of a narrow 
linear range possibly caused by ion pairing reagent, the peaks were first calibrated using 
external calibration curves and corrected by a correction factor (see Section 3.2.6) before 
calculation of fold-change, while for GC/MS, peak areas normalized to ribitol (the internal 
standard) were used directly. Peaks from LC/MS and GC/MS were integrated after 
normalization. 
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Fig. 3-3. (A) Normalization to internal standard, followed by Pareto-scaling. Numbers 1-4 indicate batch 
number. Batch-to-batch variation cannot be eliminated using this normalization method. Ellipse 
indicates 95% confidence border based on Hotelling’s T2 statistics. 
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Fig. 3-3. (B) Normalization to wild-type strain (log2-transformed fold-change of the metabolites relative 
to wild-type). Numbers 1-4 indicate batch number. Batch-to-batch variation was greatly reduced and 
data were evenly distributed. Ellipse indicates 95% confidence border based on Hotelling’s T2 statistics. 
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3.3.3. Clustering analysis of TF deletion strains 
The objectives of this chapter are to characterize transcription factors according to their 
metabolic profiles and derive possible metabolite-TF and TF-TF correlations, which can deepen 
our knowledge regarding transcriptional regulation. To classify TF deletion strains according 
to their metabolic profiles, hierarchical clustering analysis (HCA) was performed. HCA is a 
method which finds a hierarchy of clusters that share similar characteristics based on distance 
or similarity measure. Compared to other methods such as K-means clustering and self-
organizing map (SOM), HCA does not require a priori information about the data structure 
such as cluster number, thus it serves as a convenient unsupervised tool for interpreting complex 
experimental data 102. 
Several algorithms are available for HCA. However, selection of a proper algorithm is 
subjective and depends on the purpose of the classification and whether or not the classification 
result satisfies a pre-determined criterion. In this chapter, the clustering algorithm was chosen 
based on two criteria; 1) ability to keep the original structure of the data matrix as close as 
possible, in which differential strains with strong characteristics (large fold change values) and 
outliers can be distinguished from the rest, and 2) having reasonably distributed clusters when 
the hierarchical tree is cut at a certain cut-point. Euclidean distance is appropriate for this 
purpose, as it gives a direct measure of magnitude and thus was able to separate differential 
strains. In contrast, Pearson’s correlation provides a relative distance measure independent with 
magnitude, which made it fail to isolate differential strains. When comparing different linkage 
methods, single linkage could not generate an appropriate cut interpretation, with many small 
distorted clusters having few members. Average and complete linkages performed comparably, 
but the former had an overall structure closer to the original data matrix. Ward’s minimum 
linkage was efficient in finding compact, homogenized clusters, but incapable of filtering 
outliers. Based on these findings, Euclidean distance with average linkage was chosen as the 
clustering algorithm in this study.  
The main purpose for performing HCA is to identify differential strains and clusters. The 
procedures to identify differential strains and clusters are depicted in Fig. 3-4. First, the cut-off 
value was determined by taking into account the average fold-change value of ≥ 1.3 with p < 
0.05, to separate between “differential” and “non-differential” strains. Then, strain clusters with 
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correlation values of 0.85 or more were identified. Differential strains here refer to the strains 
that have large differences in metabolic profiles compared with wild-type. 
Using the metabolome dataset of log2 fold-change values, hierarchical clustering analysis 
was performed (Fig. 3-5). Here, the farther a strain is located on the outer hierarchy, the more 
differential it is relative to the control. Table 3-2 summarizes cluster sets obtained from HCA. 
Here, the 154 transcription factor deletion strains can mainly be categorized into four groups; 
1) differential, no clusters, 2) differential and formed clusters, 3) not differential and formed 
clusters, and 4) not differential, no clusters. A total of 27 strain clusters and two sets of no-
cluster were obtained.  
 
Fig. 3-4. Schematic diagram showing the procedures to determine differential strains as well as clusters. 
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Fig. 3-5. Heat map showing metabolite changes in 154 transcription factor-related mutant strains 
analyzed in this study. Clustering was based on hierarchical clustering analysis, HCA using log2 
normalized to the wild-type strain (fold-change) dataset. The clustering parameters were as follows: 
Euclidean distance and average linkage for strain clustering; Pearson’s r and average linkage for 
metabolite clustering. The more differential a strain is, the farther it is located from the center and closer 
to the outer hierarchy. 
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Table 3-2 List of differential strain clusters obtained from hierarchical clustering. Strains were 
listed in hierarchical importance (i.e., from outer to inner hierarchy). 
Group  Cluster Members Correlation 
1: Differential, no 
clusters 
- arg82∆, ada2∆, sef1∆, swi6∆, aft1∆, 
cbf1∆, gcr2∆, ada3∆, sin3∆, gln3∆, 
stb5∆, rpn4∆ 
- 
    
2: Differential  
and formed 
clusters  
1 ino2∆, ino4∆, opi1∆, ric1∆ 0.85 
2 pho23∆, stp2∆ 0.86 
3 mks1∆, rrn10∆, rtg3∆, rtg1∆ 0.87 
4 mac1∆, sum1∆ 0.89 
5 cst6∆, sds3∆ 0.92 
6 sfl1∆, usv1∆, azf1∆, rlm1∆  0.92 
7 sas2∆, ccr4∆  0.91 
8 gcn4∆, hap3∆, met31∆ 0.89 
9 yap1∆, hir1∆, tec1∆ 0.91 
10 ixr1∆, hal9∆, rim101∆, tuf1∆ 0.91 
11 ace2∆, dal81∆, tea1∆, ash1∆ 0.92 
12 ppr1∆, skn7∆ 0.95 
    
3: Not differential 
and formed 
clusters  
13 ecm22∆, hap4∆, aro80∆, fzf1∆, 
arg80∆, uga3∆ 
0.95 
14 met28∆, oaf1∆ 0.95 
15 bas2∆, bas1∆, ime1∆, lys14∆, leu3∆, 
cad1∆/yap2∆, dal80∆, yap6∆, mot3∆, 
pho4∆, stp1∆  
0.96 
16 hap2∆, hap5∆, thi2∆ 0.95 
17 msn1∆, aft2∆, arr1∆, yap5∆, cin5∆, 
crz1∆, pdr8∆, cha4∆, msn4∆, rgt1∆, 
pdr3∆, msn2∆, cat8∆, sko1∆, yap7∆, 
xbp1∆, wtm2∆, mig2∆, pdr1∆, sut1∆, 
ume6∆, tye7∆, yrr1∆ 
0.96 
18 nrg1∆, yap3∆ 0.95 
19 adr1∆, hac1∆, smp1∆, yrm1∆ 0.95 
20 gat3∆, gat2∆, put3∆, gat1∆, gis1∆, 
gat4∆, spt23∆, mal33∆, dal82∆, rsf2∆, 
zap1∆, mig1∆, mig3∆, mal13∆, rgm1∆ 
0.94 
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The cut-point for “differential” in HCA is justified by average deviation from the mutant 
median and Hotelling's T2 values (Table 3-3). A strain is defined as differential if it is located 
outside the confidence border of 95% based on T2 statistics on PCA plot or having an average 
deviation from the mutant median of ≥ 1.3. The Hotelling’s T2 is the multivariate extension of 
the common two group Student’s t-test. In a t-test, differences in the mean response between 
two populations are studied. T2 is used when the number of response variables is two or more, 
although it can be used when there is only one response variable. The null hypothesis is that the 
group means for all response variables are equal.  
Average deviation from the mutant median specifically denotes the average deviation from 
the median of mutant measurement, and was employed as an alternative measure of difference, 
independent from the wild-type strain BY4742, since there is a possibility that the wild-type 
profile is distorted in some metabolites. Average deviation from the mutant median was 
calculated as follows: the concentration of each metabolite in individual sample was divided by 
the median value of the metabolite concentration across all mutants, summed over all 
metabolites, and averaged over the number of metabolites. Division, instead of subtraction was 
used considering the different magnitudes of metabolite intensity values, to avoid 
overrepresentation of metabolites with large magnitude/highly abundant metabolites. 
21 cup9∆, argr2∆, gal3∆, gal4∆, 
ace1∆/cup2∆, mga1∆, gal80∆, ssn6∆, 
sut2∆ 
0.96 
22 sir3∆, sir4∆, sir1∆, zds2∆ 0.96 
23 hms1∆, fkh2∆, yhp1∆  0.95 
24 rox1∆, hir2∆, hir3∆ 0.96 
25 ezl1∆, ndt80∆, fkh1∆, rfx1∆, phd1∆, 
flo8∆, wtm1∆, zds1∆, yox1∆, kar4∆, 
rph1∆, swi4∆, swi5∆ 
0.94 
26 hcm1∆, mbp1∆ 0.95 
27 sir2∆, tsp1∆ 0.94 
    
4: Not differential, 
no clusters 
- gzf3∆, sip4∆, not3∆, uaf30∆ - 
66 
 
Table 3-3. List of differential strains based on average deviation from mutant values and 
Hotelling’s T2 statistics. 
No. Strain 
Average deviation 
from the mutant 
mediana 
Hotelling's T2 
Rangeb 
Groupc 
1 arg82∆ 3.16 96.77 1 
2 ada2∆ 1.85 69.95 1 
3 aft1∆ 1.50 40.62 1 
4 gcn4∆ 1.44 11.31 2 
5 azf1∆ 1.43 22.83 2 
6 swi6∆ 1.37 54.94 1 
7 usv1∆ 1.37 19.70 2 
8 ino2∆ 1.37 35.02 2 
9 sum1∆ 1.37 25.15 2 
10 mac1∆ 1.32 13.86 2 
11 ada3∆ 1.32 50.20 1 
12 gln3∆ 1.31 15.62 1 
13 rlm1∆ 1.30 15.04 2 
14 tea1∆ 1.30 5.19 2 
15 cbf1∆ 1.30 12.82 1 
16 sin3∆ 1.30 13.68 1 
17 sas2∆ 1.30 6.96 2 
18 ace2∆ 1.29 13.76 2 
19 cst6∆ 1.28 30.21 2 
20 dal81∆ 1.26 7.75 2 
a 
∑ /	


, X: metabolite concentration in individual mutant, M: median of metabolite 
concentration across all mutants, i, …, n: metabolite ID. This value was averaged over 
replicate number (3) for each strain, and ≥ 1.3 is defined as differential. 
b based on PCA with eleven significant principal components (SIMCA-P+ ver13, Umetrics, 
Umeå, Sweden) (Supplementary Table S6). Italicized values indicate less than 95% 
confidence range (< 21.85). 
c refers to the group designation in HCA (Table 3-2). 
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Moreover, clustering of metabolites based on correlation on Fig. 3-5 revealed that 
metabolites that share similar pathway (e.g., amino acids biosynthesis) or having similar 
chemical structure (e.g., nucleotides, sugar phosphates) tended to be grouped together or closely 
positioned with each other. Five metabolites, namely arginine, histidine, guanine, inosine and 
guanosine indicated significant changes (p < 0.05) in more than 70% of the mutant strains, 
which could possibly be a unique characteristic of BY4742 derivatives, whereas pyroglutamate, 
fructose 6-phosphate and melibiose were altered in only 2 out of 154 mutants (Supplementary 
Table S7). In terms of between-metabolite correlations, the highest correlation (Pearson’s r 
0.922) was observed between 1,3-bisphosphoglycerate and phosphoenolpyruvate which are two 
intermediates of glycolysis. Other strong correlations were mainly exhibited by amino acids 
and nucleotides (Table 3-4). 
 
Table 3-4. Between-metabolite correlations (≥0.6). 
Positive correlation Negative correlation 
Metabolites Pearson’s r Metabolites Pearson’s r 
1,3-BPG-PEP 0.922 Phenylalanine-NADP -0.653 
Phosphate-glucose 0.902 Methionine-NADP -0.643 
F1,6-F2,6P 0.858 Phenylalanine-F2,6P -0.629 
Methionine-tyrosine 0.838 Methionine-F2,6P -0.608 
Tyrosine-phenylalanine 0.837 Citrate-PEP -0.601 
Alanine-glycine 0.813 Phenylalanine-GDP -0.601 
Glutamate-2-oxoglutarate 0.802   
Isoleucine-phenylalanine 0.794   
Methionine-isoleucine 0.776   
NADP-F2,6P 0.776   
Isoleucine-tyrosine 0.775   
Phenylalanine-tryptophan 0.775   
CTP-GTP 0.770   
CTP-UTP 0.768   
Glycine-leucine 0.761   
Uracil-inositol 0.753   
UMP-2-isopropylmalate 0.752   
Methionine-phenylalanine 0.751   
AMP-ADP 0.745   
3-aminoethanol-glucose 0.744   
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Inosine-guanosine 0.731   
GTP-ATP 0.717   
R5P-Ru5P 0.713   
Uracil-melibiose 0.701   
Asparagine-methionine 0.698   
Proline-methionine 0.695   
Alanine-leucine 0.686   
2-aminoethanol-phosphate 0.679   
F6P-F1P 0.678   
CDP-ADP 0.674   
Asparagine-tyrosine 0.673   
Tyrosine-asparagine 0.673   
Serine-aspartate 0.648   
Serine-asparagine 0.636   
Pyruvate-UMP 0.634   
NAD-ATP 0.633   
GMP-ADP 0.615   
Asparagine-aspartate 0.614   
Tyrosine-tryptophan 0.611   
Arginine-histidine 0.610   
GAP-DHAP 0.604   
UMP-PEP 0.602   
GMP-AMP 0.602   
Guanine-guanosine 0.601   
Methionine-aspartate 0.601   
Abbreviations: 1,3BPG: 1,3 bisphosphoglycerate; PEP: phosphoenolpyruvate; F1,6P: fructose 1,6-
bisphosphate; F2,6P: fructose 2,6-bisphosphate; R5P: ribose 5-phosphate; Ru5P: ribulose 5-phosphate; 
F6P: fructose 6-phosphate; F1P: fructose 1-phosphate; GAP: glyceraldehyde 3-phosphate; DHAP: 
dihydroxyacetone phosphate; NAD: nicotinamide adenine dinucleotide; NADP: nicotinamide adenine 
dinucleotide phosphate; ATP: adenosine 5’-triphosphate; ADP: adenosine 5’-diphosphate; AMP: adenosine 
5’-monophosphate; GTP: guanosine 5’-triphosphate; GDP: guanosine 5’-diphosphate; GMP: guanosine 5’-
monophosphate; CTP: cytidine 5’-triphosphate; CDP: cytidine 5’-diphosphate; UMP: uridine 5’-
monophosphate. 
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3.3.4. Analysis of differential strains 
Characterization of deletion strains based on HCA (Fig. 3-5 and Table 3-2) revealed that 
twelve strains have differential and unique metabolic profiles. 36 more strains showed 
differential profile and formed clusters. HCA result is in accordance with differential analysis 
as depicted in Table 3-3, in which strains with high average deviation from the mutant median 
and T2 values were located at the outer hierarchy of HCA, and thus belong to Group 1 or 2. 
Within these two groups, six disruptants strains (gcr2∆ disruptant, aft1∆ disruptant, ada2∆ 
disruptant, ino2∆ disruptant, ino4∆ disruptant, opi1∆ disruptant) showed growth defect of > 
20% and six (rpn4∆ disruptant, arg82∆ disruptant, sin3∆ disruptant, swi6∆ disruptant, cbf1∆ 
disruptant, ada3∆ disruptant) had somewhat lower maximum specific growth rate compared to 
control, suggesting that altered metabolism is likely to be related with poor growth. To test 
whether the metabolic phenotype is a function of growth rate, Pearson’s correlation coefficient 
was calculated between maximum specific growth rate (µ) and average deviation from the 
mutant median and Hotelling’s T2 range, and between µ and each metabolite in these twelve 
strains. If the transcription factors have an indirect effect on metabolite distributions via reduced 
growth rates in the deletion mutants, a correlation between mutant growth rates and the 
metabolic profile (expressed as the average deviation from the mutant median and Hotelling’s 
T2) is expected 84. As a result, average deviation from the mutant median and Hotelling’s T2 
were not correlated with growth rate (correlation coefficients were 0.17 and -0.08 respectively), 
indicating that metabolic profile alteration was directly due to the gene deletion and not 
indirectly influenced by poor growth. Almost all metabolites also showed no correlation with 
the maximum specific growth rate, with the exception of four metabolites i.e., trehalose, 
glyceraldehyde 3-phosphate (GAP) and its isomer dihydroxyacetone phosphate (DHAP), and 
2-oxoglutarate, in which the correlation coefficients were -0.72, 0.72, 0.64, and 0.68 
respectively. It was reported that trehalose and glycogen accumulate in S. cerevisiae when 
growth condition deteriorates, suggesting that these carbohydrates may be required for cell 
cycle progression at low growth rates 103. In a separate study, intracellular DHAP+GAP was 
found to increase in response to an increase in growth rate in E. coli 104. However the association 
between 2-oxoglutarate with growth rate is presently unclear. 
In this study, arg82∆ disruptant was identified as the most differential strain with the highest 
values of the average deviation from the mutant median and Hotelling’s T2 (Table 3-3). Arg82 
70 
 
was originally identified as a regulator of arginine biosynthesis 105. Arg82 is also an inositol 
polyphosphate multikinase (IPMK), a global regulator involved in the regulation of arginine-, 
phosphate-, and nitrogen-responsive genes 106. Arginine level was increased (fold-change=1.5) 
in arg82∆ disruptant, in agreement with a previous study that reported mutation in ARG82 leads 
to constitutive production of the arginine biosynthetic enzymes encoded by the ARG1, ARG3, 
ARG5,6 and ARG8 genes 107. Deletion of ARG82 also caused altered levels of various 
metabolites, mainly amino acids but includes TCA cycle intermediates and co-factors such as 
UTP and ATP. The most apparent was 370-fold change in citrate level. TF association search 
using YEASTRACT 108 (Yeast Search for Transcriptional Regulators And Consensus 
Tracking) showed no association between Arg82 and the genes encoding citrate synthase. 
However, two regulatory proteins, Arg80 and Mcm1, that have been reported to be stabilized 
by Arg82 109, showed positive association with CIT1 21. This observation suggests that Arg82 
might regulate citrate metabolism indirectly through the interaction with other TFs. More 
importantly, arg82∆ disruptant showed a great level of metabolic alteration, with an average 
deviation from the mutant median of 3.16 vs. 1.85 in the second most differential strain, ada2∆ 
disruptant. Arg82 has been described as a global regulator 107, thus this finding suggests that 
ARG82 may take part in more metabolic regulations than previously reported. 
In addition, differential profile in ada2∆ disruptant and ada3∆ disruptant was also observed. 
Ada2 and Ada3 are dual function regulators involved in the regulation of many other 
transcription factors, and component of three chromatin modifying histone acetyltransferase 
(HAT) complexes: SAGA, SLIK and ADA complexes (reviewed in Sterner and Berger (2000) 
110). Between these two strains, ada2∆ disruptant exhibited a larger variation in metabolic 
profile compared to ada3∆ disruptant (average deviation from mutant median of 1.85 and 1.32 
respectively). While both shared similar metabolic pattern in some metabolites such as amino 
adipic acid, inosine, orotate, succinate, malate (increased) and alpha-glycerophosphate, 
glutathione, CMP, pyruvate, nicotinate (decreased), only ada2∆ disruptant showed a marked 
change in citrate, 1,3-bisphosphoglycerate and phosphoenolpyruvate levels. Besides, there was 
no strong correlation in metabolic profile between ada2∆ and ada3∆ disruptants (correlation 
coefficient was 0.59). The different degree and configuration of metabolic alteration between 
ada2∆ disruptant and ada3∆ disruptant suggests that, while Ada2 and Ada3 share a common 
function in some regulations (i.e., in the histone modification 110), there might be additional 
pathways exclusively affected by only one of the TFs. 
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3.3.5. Analysis of functionally related strains 
Another interesting feature observed from HCA based on metabolome dataset was the 
ability to screen a specific group of strains with related functions. From Table 3-2, ino2∆, ino4∆, 
opi1∆, ric1∆ cluster (correlation coefficient 0.85) can be found. This cluster is characterized by 
a marked increase in trehalose, succinate and citrate, as well as decrease in proline, guanosine 
and 1,3-bisphosphoglycerate (Fig. 3-6 (A)). Ino2, Ino4 and Opi1 engage in inositol metabolism 
and glycerolipids regulation 111–113. Interestingly, ino2∆, ino4∆ and opi1∆ disruptants all 
showed growth defect of >20% compared to control, with remarkably high correlation in 
metabolic profile, while the association of Ric1 with these three regulators has not been 
described yet. Similarly, mks1∆, rtg3∆, rtg1∆ and rrn10∆ disruptants formed a cluster with 
high correlation (0.87). This cluster share a similar feature of decreased amino adipic acid, 
glutamate and 2-oxoglutarate (Fig. 3-6 (B)). While Mks1, Rtg1 and Rtg3 have been previously 
demonstrated to be involved in mitochondrial retrograde response (RTG) in yeast 41,49,51, there 
was no report about the involvement of Rrn10. Here, mks1∆ disruptant showed the same 
metabolic profile as rtg1∆ and rtg3∆ disruptants, contradicted to its purported role as a negative 
regulator of RTG pathway 51. Interestingly, large-scale transcriptomics data from Kemmeren et 
al. (2014) 76 also revealed a similar transcript pattern between mks1∆ and rtg1∆ or rtg3∆ 
disruptants. The discrepancy in MKS1 deletion was probably due to the difference in the 
background strain as reported previously 114. 
The findings in this chapter demonstrated the possibility of novel gene function exploration 
based on metabolic phenotype that can be unraveled by metabolomics. Further studies 
regarding these uncharacterized roles of transcription factors would be an interesting topic for 
future studies. Overall, more metabolic change was found in terms of the number of correlations 
and significantly altered metabolites compared to previous reports 84,85, and thus verified the 
high resolution approach of metabolomics employed in this study. However, it is important to 
note that transcriptional regulation is condition-specific and tightly controlled. In this chapter, 
only a ‘standard’ growth condition is examined. Therefore, investigation of regulations that are 
activated or repressed only during a specific condition should be performed under a defined 
experimental set-up and might involve time-series profiling. Moreover, some transcription 
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factors can take part in multiple pathways, resulting in compounding effects in the final 
metabolic profile. Un-assembling of these pathways requires thorough consideration and 
further experiments, such as flux measurement and kinetic modeling to investigate allosteric 
protein-metabolite interactions 115. 
Additionally, BY4742 derivatives which carry multiple gene deletions were used here. Use 
of a prototrophic strain collection 116 may yield less bias caused by auxotrophic markers and 
feasible with minimal media, thereby reducing the compounding factors posed by additional 
nutrient supplementation. Nonetheless, useful TF-metabolites correlations were obtained which 
can be used to predict or generate new working hypotheses regarding the function of the TFs. 
For future studies, researchers can select only cluster of interest and conduct further 
experiments under a more defined condition based on the hints provided by metabolic profile 
similarity. Further examination of less differential clusters but share highly similar metabolic 
pattern (i.e., clusters in Group 3 in Table 3-2) might also reveal other previously unknown 
correlations and lead to better understanding of transcriptional regulations.  
 
3.3.6. Comparison with transcriptomics analysis 
Transcriptomics analysis using microarrays has been the leading approach for functional 
characterization of TFs, by which the gene expression levels are examined (up-regulated or 
down-regulated), usually under the deletion of the TF. Currently, the YEASTRACT 108 
repository provides a convenient platform for researchers to find TF-gene associations, based 
on more than 1300 bibliographic references. Many researchers also deposit their raw microarray 
data into public repositories such as the Gene Expression Omnibus (GEO) 117 and ArrayExpress 
118. However, the most widely recognized limitation of microarrays is the low reproducibility 
observed when using different array platforms 119. This is usually the result of probe-specific 
effects such as oligonucleotide probes versus PCR product probes, and array-synthesis effects 
such as on-slide synthesis versus robotic spotting. 
When studying the effects of TF deletion towards metabolism, transcriptomics data alone 
may not be sufficient. While the interpretation of genes encoding an enzyme that catalyzes 
specific metabolic pathways is rather straightforward, for genes encoding a permease, for 
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example, it might be difficult to judge what happens to the cell by only looking at the transcript 
levels. For instance, in Section 2.3.5., the deletion of Rtg1 and Rtg3 resulted in the decreased 
concentrations of TCA cycle intermediates, in agreement with the decrease in transcript levels 
of the genes encoding TCA cycle enzymes. However, for amino acids, it is difficult to predict 
the intracellular concentrations based on transcript levels only, because apart from de novo 
synthesis and degradation, they may also be up taken from the medium by a general (non-
specific) transporter. Moreover, metabolic alteration may also occur even when the TF does not 
seem to have gene targets in that pathway through transcriptional cascade, i.e., via the 
interaction with other TFs. For example, in Section 3.3.4., the change in citrate in arg82∆ 
disruptant was not seen at the transcript level and is likely due to the interaction of Arg82 with 
Arg80 and Mcm1 proteins.  
In transcriptomics analysis, a standard RNA extraction protocol can practically extract all 
the RNAs at one time. In contrast, metabolites are composed of molecules with diverse 
chemical properties (polarity, water-solubility, volatility, etc.) that necessitate different 
extraction techniques, making comprehensive metabolite profiling very challenging. In addition, 
raw mass spectral data are huge in size and difficult to manage in a repository, and require large 
funding and trained specialists to extract the data. However, some research groups (e.g., Fiehn 
group from UC Davis, USA 120) already started the initiative of making a metabolomics data 
repository, so that datasets from various researchers under various conditions and extraction 
methods can be combined and analyzed simultaneously. The availability of public cumulated 
data is expected to lead to new discoveries that are only possible with large diverse datasets. 
 
  
74 
 
 
Fig. 3-6. Heat map of metabolite fold-change in two representative differential clusters (A) Cluster 1 (ino2∆, ino4∆, opi1∆, ric1∆) and (B) 
Cluster 3 (mks1∆, rtg1∆, rtg3∆, rrn10∆). For example, in Cluster 1, although Ino2, Ino4 and Opi1 genes have been associated with inositol 
and phospholipid regulation, the role of Ric1 in these regulatory pathways has not been reported. Clustering of strains that share similar 
metabolic profiles proves to be useful in finding both known and new gene/TF-metabolite correlations. 
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3.4. Conclusions 
A global analysis of gene-metabolite correlations in 154 transcription factor deletion strains 
was conducted. Metabolome dataset provides useful insights into the effects of transcription 
factor deletion towards metabolic pathway rearrangement. Metabolites as the final readouts of 
gene transcription process can help delineate the complex rearrangement of metabolism under 
TF deletion which may not be always evident in transcript levels. Characterization of deletion 
strains using principal component analysis and hierarchical clustering analysis proved to be 
useful for the screening of differential and functionally related strains/genes. Both previously 
reported and possibly new correlations were obtained. This information can be used to open the 
doors to deeper investigations. The metabolome dataset presented in this chapter does not only 
provide information about key metabolites but also represents a useful resource for future 
transcriptional regulation studies.  
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Chapter 4 Conclusions and perspectives 
 
The complete elucidation of cellular functions is an enormous effort and requires various 
strategies to capture the entire system. Metabolomics-based gene-metabolite correlation 
analysis is a practical and useful method to unravel new working hypotheses on the basis of 
metabolic phenotype. In this study, the application of metabolomics in studying metabolic 
alteration caused by TF deletion was investigated.  
By comprehensive metabolic profiling, the differences between wild type and mutant 
strains defective in specific transcription factor-encoding genes were observed. Relative 
comparison of metabolic profiles using wild-type and knock-out strains proved to be useful in 
deriving possible regulatory pathways controlled by the transcription factors. In the first part of 
the thesis, I demonstrated the application of metabolic profiling in understanding retrograde 
regulation in yeast, by two bHLH regulators Rtg1 and Rtg3. The remarkable decrease in 2-
oxogluratarate was reported to be the hallmark of RTG-gene perturbation. Additionally, a 
change in polyamine biosynthesis was also observed.  
In the second part, I applied metabolomics-based screening for the characterization of 154 
disruptant strains each defective in a gene encoding a transcription factor. Using two 
multivariate data analysis methods, principal component analysis and hierarchical clustering 
analysis, I assigned the deletion strains into several clusters according to their metabolic 
signatures. Several TF-gene and TF-TF correlations were discussed, covering both known and 
previously unreported observations.  
At present, functional assignment of TFs is not yet complete 17,81,82. There are also 
inductions or repressions of pathways that do not seem to be the direct target of the TF, which 
are probably due to transcriptional cascades 82. In silico sequence homology analysis using 
computational methods has been the main tool for annotation and contributes vastly to our 
understanding of TF/gene regulation, but this approach cannot assign orphan genes with little 
or no homology to existing databases, and misannotation may occur since two genes can have 
very similar sequences but function differently 121. For example, a gene sequence with a gene 
identifier, gi: 71915096 (GenBank:AAZ54998) was annotated as an o-succinylbenzoate 
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synthase (OSBS) in GenBank database 122 based on its high score against OSBS family, 
although this sequence contains a number of additional substitutions in sequence motifs 
conserved in authentic members of the OSBS family, an error known as ‘MRF’ (Missing 
Functionally important Residue(s)) 123. This gene sequence was later shown to likely represent 
a new and unknown function in the enolase superfamily, rather than an OSBS 124. In this regard, 
a global approach such as metabolomics is a more advanced option since not only it directly 
measures the effect of a gene deletion and allows characterization of genes according to 
metabolic profile similarity, but may also lead to novel discovery of biochemical pathways, 
such as demonstrated previously by the discovery of riboneogenesis in yeast 125. 
To enable genome-wide metabolic profiling, specifically these factors must be taken into 
account; 1) a reliable and reproducible high-throughput analysis platform which covers as many 
metabolites as possible, 2) a reproducible and stable sample extraction protocol that ensures 
efficient recovery of various metabolites, 3) a robust peak-picking and alignment algorithm, 
and 4) a sophisticated data analysis software and curated database that allows cross-referencing 
with up-to-date research finding.  
Ultimately, functional assignment of all genes is desirable, but this task requires huge and 
concerted effort from various researchers, as validation experiments (‘omics’ and other systems 
biology approaches) are laborious, highly sophisticated and technologically demanding. 
Moreover, the massive data from omics approaches require careful selection of candidate 
targets, and an appropriate statistical analysis must be performed to minimize false negatives 
and false positives. This study represents a small, but nonetheless, a significant portion of this 
effort. Undoubtedly, metabolomics, together with other omics, can aid the identification of 
important target genes and/or proteins, to be applied for example in the engineering of strains 
with improved phenotype (by overexpression or knockout of the identified target genes) or 
screening of target molecules for drug development. It is expected that metabolomics will be 
routinely performed, whether as a primary or complementary means in many gene regulation 
studies. 
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Appendices 
Supplementary Table S1. Optimized multiple reaction monitoring (MRM) parameters and 
retention time for each metabolite, measured by LC-MS/MS. 
No Metabolite 
LC-MS 
Method*/mode 
Precursor 
ion m/z 
Product 
ion m/z 
Retention 
Time 
(min) 
Target 
Q1 
Pre 
Bias 
(V) 
Target 
Collision 
Energy 
(V) 
Target 
Q3 
Pre 
Bias 
(V) 
1 Arginine 
Ion-pair RP/ESI 
negative 
173.10 131.20 1.039 13 15 24 
2 Histidine 
Ion-pair RP/ESI 
negative 
154.00 93.15 1.038 12 21 16 
3 Serine 
Ion-pair RP/ESI 
negative 
104.00 74.15 1.138 12 16 13 
4 Asparagine 
Ion-pair RP/ESI 
negative 
131.00 113.15 1.151 10 15 21 
5 Glutamine 
Ion-pair RP/ESI 
negative 
145.00 127.05 1.160 12 18 18 
6 Threonine 
Ion-pair RP/ESI 
negative 
118.00 74.05 1.186 11 15 13 
7 Trehalose 
Ion-pair RP/ESI 
negative 
341.00 89.00 1.302 15 23 16 
8 Proline 
Ion-pair RP/ESI 
negative 
114.00 68.10 1.331 10 15 11 
9 Methionine 
Ion-pair RP/ESI 
negative 
148.00 47.05 1.987 11 14 16 
10 Isoleucine 
Ion-pair RP/ESI 
negative 
130.10 45.00 2.578 11 15 15 
11 Adenine 
Ion-pair RP/ESI 
negative 
134.05 107.35 2.829 28 20 20 
12 Tyrosine 
Ion-pair RP/ESI 
negative 
180.00 163.05 2.834 12 18 18 
13 Xanthine 
Ion-pair RP/ESI 
negative 
151.20 108.15 3.000 16 20 19 
14 Amino adipic acid 
Ion-pair RP/ESI 
negative 
160.00 116.20 3.171 12 17 21 
15 Glutamate 
Ion-pair RP/ESI 
negative 
146.00 102.20 3.273 11 15 18 
16 Aspartate 
Ion-pair RP/ESI 
negative 
132.00 88.05 3.467 10 14 15 
17 Inosine 
Ion-pair RP/ESI 
negative 
267.00 135.15 4.559 21 23 24 
18 Guanosine 
Ion-pair RP/ESI 
negative 
282.10 150.20 4.706 22 21 28 
19 Phenylalanine 
Ion-pair RP/ESI 
negative 
164.00 103.15 4.854 13 18 19 
20 Glycolate 
Ion-pair RP/ESI 
negative 
75.00 75.00 5.001 16 15 15 
21 Glycerate 
Ion-pair RP/ESI 
negative 
105.00 75.15 5.088 12 15 26 
22 Adenosine 
Ion-pair RP/ESI 
negative 
266.10 134.15 5.385 18 20 26 
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23 Glyoxylate 
Ion-pair RP/ESI 
negative 
73.00 73.00 5.577 14 13 15 
24 Pyroglutamate 
Ion-pair RP/ESI 
negative 
128.00 84.10 6.438 10 14 15 
25 Glucose 6-phosphate 
Ion-pair RP/ESI 
negative 
258.90 97.05 6.734 20 21 17 
26 
PIPES (Internal 
standard) 
Ion-pair RP/ESI 
negative 
301.00 193.25 6.949 12 28 21 
27 
Sedoheptulose 7-
phosphate 
Ion-pair RP/ESI 
negative 
288.90 97.10 7.001 23 23 17 
28 Fructose 6-phosphate 
Ion-pair RP/ESI 
negative 
258.90 97.10 7.058 20 15 17 
29 Ribose 5-phosphate 
Ion-pair RP/ESI 
negative 
229.10 96.95 7.067 18 13 18 
30 Tryptophan 
Ion-pair RP/ESI 
negative 
203.10 116.15 7.070 16 18 21 
31 a-Glycerophosphate 
Ion-pair RP/ESI 
negative 
171.10 79.10 7.226 13 16 13 
32 Glutathione 
Ion-pair RP/ESI 
negative 
305.90 143.20 7.536 21 19 26 
33 Ribulose 5-phosphate 
Ion-pair RP/ESI 
negative 
229.00 97.10 7.767 17 13 17 
34 Orotate 
Ion-pair RP/ESI 
negative 
155.00 111.15 7.928 12 14 20 
35 CMP 
Ion-pair RP/ESI 
negative 
322.00 79.10 8.099 25 28 13 
36 Fructose 1-phosphate 
Ion-pair RP/ESI 
negative 
258.90 97.05 8.102 20 21 17 
37 NAD 
Ion-pair RP/ESI 
negative 
662.10 540.10 8.281 26 18 26 
38 Pyruvate 
Ion-pair RP/ESI 
negative 
87.00 43.05 8.318 10 11 14 
39 DHAP 
Ion-pair RP/ESI 
negative 
168.90 97.05 8.608 13 12 17 
40 UMP 
Ion-pair RP/ESI 
negative 
322.90 97.10 8.815 25 24 17 
41 GMP 
Ion-pair RP/ESI 
negative 
362.00 79.10 8.995 29 28 13 
42 Oxalacetate 
Ion-pair RP/ESI 
negative 
131.00 87.00 9.310 25 11 27 
43 TMP 
Ion-pair RP/ESI 
negative 
321.00 79.10 9.719 25 38 14 
44 AMP 
Ion-pair RP/ESI 
negative 
346.00 79.05 9.811 14 32 14 
45 Nicotinate 
Ion-pair RP/ESI 
negative 
122.00 78.15 9.983 14 15 13 
46 Pantothenate 
Ion-pair RP/ESI 
negative 
218.00 88.00 10.022 21 14 16 
47 Succinate 
Ion-pair RP/ESI 
negative 
117.00 73.20 10.155 13 15 12 
48 Fumarate 
Ion-pair RP/ESI 
negative 
115.00 71.10 10.278 13 10 12 
49 cAMP 
Ion-pair RP/ESI 
negative 
328.00 134.10 10.465 15 27 24 
91 
 
50 Malate 
Ion-pair RP/ESI 
negative 
132.90 115.20 10.578 10 17 21 
51 UDP-glucose 
Ion-pair RP/ESI 
negative 
564.80 323.10 10.712 24 26 15 
52 2-Oxoglutarate 
Ion-pair RP/ESI 
negative 
145.00 101.20 10.745 11 13 18 
53 CDP 
Ion-pair RP/ESI 
negative 
401.80 79.05 10.753 16 43 13 
54 UDP 
Ion-pair RP/ESI 
negative 
402.90 79.05 10.807 16 48 13 
55 NADP 
Ion-pair RP/ESI 
negative 
741.80 620.10 10.811 26 18 30 
56 3Phosphoglycerate 
Ion-pair RP/ESI 
negative 
184.90 97.05 10.829 14 16 17 
57 
Fructose 2,6-
bisphosphate 
Ion-pair RP/ESI 
negative 
338.90 241.15 10.834 26 19 27 
58 
Fructose 1,6-
bisphosphate 
Ion-pair RP/ESI 
negative 
338.90 97.10 10.838 26 22 17 
59 NADH 
Ion-pair RP/ESI 
negative 
664.00 78.95 10.876 24 57 13 
60 Isocitrate 
Ion-pair RP/ESI 
negative 
190.90 73.20 10.891 13 22 26 
61 Citrate 
Ion-pair RP/ESI 
negative 
190.90 87.00 10.892 13 18 14 
62 ADP 
Ion-pair RP/ESI 
negative 
425.90 79.10 10.913 17 47 13 
63 Bisphosphoglycerate 
Ion-pair RP/ESI 
negative 
265.00 167.15 10.919 11 18 29 
64 Phosphoenolpyruvate 
Ion-pair RP/ESI 
negative 
167.00 78.95 10.928 15 13 13 
65 2-Isopropylmalate 
Ion-pair RP/ESI 
negative 
175.00 115.20 10.998 13 16 21 
66 FAD 
Ion-pair RP/ESI 
negative 
783.90 97.10 11.155 20 51 17 
67 CTP 
Ion-pair RP/ESI 
negative 
481.90 159.10 11.171 19 36 29 
68 GTP 
Ion-pair RP/ESI 
negative 
521.90 159.05 11.185 20 32 29 
69 NADPH 
Ion-pair RP/ESI 
negative 
744.00 159.00 11.201 26 60 30 
70 UTP 
Ion-pair RP/ESI 
negative 
482.90 159.10 11.206 19 36 29 
71 ATP 
Ion-pair RP/ESI 
negative 
505.90 159.10 11.226 20 35 29 
72 Acetyl-coA 
Ion-pair RP/ESI 
negative 
808.00 408.00 11.382 20 37 28 
73 Cystine RP/ESI positive 241.05 74.00 1.349 -25 -40 -14 
74 Hydroxyproline RP/ESI positive 131.70 85.95 1.437 -30 -19 -14 
75 Cysteine RP/ESI positive 122.00 59.00 1.482 -29 -40 -13 
76 Homoserine RP/ESI positive 119.70 74.15 1.514 -30 -15 -12 
77 Alanine RP/ESI positive 90.05 44.05 1.563 -16 -20 -19 
78 Citrulline RP/ESI positive 175.60 70.00 1.572 -30 -30 -30 
79 Ornithine RP/ESI positive 132.70 69.75 1.721 -30 -30 -30 
80 Lysine RP/ESI positive 146.70 83.95 1.783 -30 -25 -13 
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81 b-Alanine RP/ESI positive 89.90 30.15 1.850 -14 -15 -30 
82 Uracil RP/ESI positive 113.15 70.05 2.278 -19 -43 -29 
83 4-Aminobutyrate RP/ESI positive 103.70 87.05 2.302 -30 -16 -15 
84 Putrescine RP/ESI positive 88.80 71.70 2.375 -30 -20 -30 
85 Glycine RP/ESI positive 118.05 43.05 2.829 -17 -40 -13 
86 Valine RP/ESI positive 118.10 72.10 2.857 -19 -10 -29 
87 Spermidine RP/ESI positive 145.70 72.20 3.130 -30 -20 -30 
88 Hypoxanthine RP/ESI positive 137.05 55.05 3.236 -21 -40 -28 
89 Uridine RP/ESI positive 244.90 113.05 3.322 -27 -10 -15 
90 Guanine RP/ESI positive 151.95 135.05 3.619 -29 -20 -16 
91 S-Adenosylmethionine RP/ESI positive 398.50 250.20 3.632 -30 -17 -25 
92 Cytidine RP/ESI positive 244.00 112.05 4.224 -16 -20 -16 
93 Deoxycytidine RP/ESI positive 228.10 112.10 5.629 -25 -10 -24 
94 Leucine RP/ESI positive 131.70 43.05 6.203 -30 -25 -17 
95 Deoxyguanosine RP/ESI positive 268.00 152.00 6.222 -18 -10 -15 
96 Thymidine RP/ESI positive 243.10 127.05 6.436 -27 -10 -29 
97 Deoxyadenosine RP/ESI positive 252.10 136.10 6.890 -17 -20 -27 
*RP: reversed phase 
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Supplementary Table S2. Summary of PCA with five significant components performed for 
metabolome dataset from metabolic profiling of BY4742 and RTG deletion strains. 
Component R2X 
R2X 
(cum) 
Eigen 
value 
Q2 Limit 
Q2 
(cum) 
Significance Iterations 
0 Cent.        
1 0.537 0.537 19.3 0.507 0.0378 0.507 R1 9 
2 0.135 0.672 4.87 0.182 0.0387 0.597 R1 75 
3 0.122 0.794 4.39 0.324 0.0396 0.728 R1 13 
4 0.0618 0.856 2.23 0.237 0.0406 0.792 R1 30 
5 0.0417 0.897 1.5 0.209 0.0417 0.835 R1 14 
 
Supplementary Table S3. Loading values on principal component 1 (PC1) and principal 
component 2 (PC2) for each metabolite (intracellular: from the yeast extract and extracellular: 
from the growth medium). 
Metabolite 
(intracellular) 
PC1 
Loading 
PC2 
Loading 
Metabolite 
(extracellular) 
PC1 
Loading 
PC2 
Loading 
2-Isopropylmalate -0.00209 0.22745 2-Isopropylmalate -0.16400 0.07362 
2-Oxoglutarate 0.00588 0.24828 2-Oxoglutarate -0.11752 0.05733 
3Phosphoglycerate 0.11976 0.00749 4-Aminobutyrate -0.14398 0.14484 
4-Aminobutyrate -0.11829 0.05978 Adenine 0.14294 0.18411 
Acetyl-coA 0.13741 0.01074 Adenosine -0.12229 0.08622 
Adenine 0.09936 -0.04542 a-Glycerophosphate -0.17368 -0.02441 
Adenosine -0.10064 -0.03844 Alanine 0.11893 -0.04041 
ADP 0.09370 0.03354 Amino adipic acid -0.15262 0.14734 
a-Glycerophosphate 0.13798 -0.00768 AMP -0.15113 0.12424 
Alanine 0.01347 -0.06582 Arginine 0.14229 0.18760 
Amino adipic acid -0.07215 0.22560 Asparagine 0.15189 0.16691 
AMP -0.10022 -0.03836 Aspartate 0.14460 0.18242 
Arginine 0.11712 0.08488 Citrate -0.13431 0.17177 
Asparagine 0.10135 -0.04259 Cystine 0.10505 -0.10305 
Aspartate 0.12016 -0.06230 Deoxyadenosine -0.17569 0.00762 
ATP 0.13473 0.05739 Deoxyguanosine -0.12206 -0.18288 
b-Alanine 0.02704 0.14669 DHAP -0.14678 -0.07630 
Bisphosphoglycerate 0.11485 0.07410 Glutamate 0.13630 0.20084 
cAMP 0.10106 -0.13327 Glutamine 0.10919 0.22477 
CDP 0.09910 -0.02309 Glutathione -0.15461 0.13571 
Citrate -0.07668 0.20449 Glycine 0.04117 0.05761 
Citrulline 0.07007 0.07924 Glycolate -0.12834 0.16408 
CMP -0.08741 -0.08178 Glyoxylate -0.08650 0.18133 
CTP 0.13086 0.05169 Guanosine -0.11670 0.07474 
Cysteine -0.06774 0.21267 Histidine 0.16084 0.04404 
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Cystine 0.13480 -0.02100 Hypoxanthine 0.13818 0.18256 
Cytidine -0.07314 0.01314 Inosine -0.16559 -0.02855 
Deoxyadenosine -0.08935 0.05245 Isocitrate -0.12434 0.17564 
Deoxycytidine 0.07273 -0.02977 Leucine 0.17279 -0.06298 
Deoxyguanosine 0.10825 -0.03625 Lysine 0.14266 0.18386 
DHAP 0.13796 -0.00388 Malate -0.17103 0.08345 
FAD 0.11104 0.03701 Methionine 0.17403 -0.04695 
Fructose 1,6-
bisphosphate 
0.13499 -0.01370 NAD -0.14924 0.12477 
Fructose 1-phosphate 0.13737 -0.01639 Nicotinate 0.14247 0.18098 
Fructose 2,6-
bisphosphate 
0.12608 -0.00098 Orotate -0.15549 -0.11610 
Fructose 6-phosphate 0.13058 0.03167 Oxalacetate 0.06816 -0.15088 
Fumarate 0.12440 0.07301 Pantothenate -0.00519 0.26084 
Glucose 6-phosphate 0.13294 0.04489 Phenylalanine 0.17340 0.02699 
Glutamate 0.11327 0.07720 Phosphoenolpyruvate -0.13665 0.16323 
Glutamine 0.08882 0.13960 Proline -0.13749 -0.02614 
Glutathione 0.11373 0.10429 Pyroglutamate 0.03414 -0.02368 
Glycerate 0.08263 0.14066 Pyruvate 0.05378 -0.24100 
Glycine 0.08802 0.15103 Serine 0.15543 0.15707 
Glycolate -0.04132 0.23183 Succinate -0.16794 0.08129 
Glyoxylate 0.00639 0.24135 Threonine 0.11451 0.22466 
GMP -0.08884 -0.07027 Thymidine -0.17320 0.04120 
GTP 0.13770 0.00852 Trehalose 0.14937 -0.02877 
Guanine 0.07134 0.00928 Tryptophan 0.15976 -0.13349 
Guanosine -0.06730 0.00043 Tyrosine 0.13203 0.15300 
Histidine -0.02338 0.23441 Uracil 0.07631 0.17593 
Homoserine 0.10027 -0.05115 Uridine -0.15427 0.09296 
Hydroxyproline 0.09716 0.06096 Valine 0.02936 0.07420 
Hypoxanthine 0.09569 -0.02078 Xanthine -0.16286 0.10989 
Inosine 0.09335 0.00044    
Isocitrate -0.06356 0.22648    
Isoleucine 0.12724 -0.02595    
Leucine 0.12801 -0.04393    
Lysine 0.11374 -0.04160    
Malate 0.01816 0.22764    
Methionine 0.12383 -0.05087    
NAD 0.09416 0.05793    
NADH 0.12883 0.01969    
NADP 0.09754 0.03847    
NADPH 0.13540 0.02288    
Nicotinate 0.09883 -0.04632    
Ornithine -0.03392 -0.12659    
Orotate 0.05678 0.13618    
Oxalacetate 0.12304 -0.02171    
Pantothenate 0.09640 0.01449    
Phenylalanine 0.13560 -0.04245    
Phosphoenolpyruvate 0.12118 0.03853    
Proline -0.04735 -0.11264    
Putrescine 0.02963 -0.16010    
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Pyroglutamate 0.13187 0.04943    
Pyruvate 0.12589 -0.04248    
Ribose 5-phosphate 0.11655 0.05339    
Ribulose 5-phosphate 0.12525 0.04431    
S-Adenosylmethionine -0.10702 0.05528    
Sedoheptulose 7-
phosphate 
0.13532 0.02000    
Serine 0.11174 -0.02229    
Spermidine -0.06151 -0.08182    
Succinate -0.08868 0.17453    
Threonine 0.05368 -0.12654    
Thymidine -0.12763 0.06990    
TMP -0.08416 -0.04919    
Trehalose -0.06462 0.16862    
Tryptophan 0.12819 -0.08465    
Tyrosine 0.10120 0.02960    
UDP 0.01583 0.04811    
UDP-glucose 0.08317 0.17915    
UMP -0.10538 -0.05556    
Uracil 0.12805 -0.01441    
Uridine -0.10055 0.07235    
UTP 0.13373 0.03512    
Valine 0.10324 0.10526    
Xanthine -0.10614 0.15427       
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Supplementary Fig. S1. (A) PCA score plot for time-course extracellular metabolic profiling 
(from growth media) of wild-type strain BY4742, and rtg1∆ and rtg3∆ disruptants (n=3). The 
metabolites were scaled to unit variance. Ellipse indicate 95% confidence border based on 
Hotelling’s T2. (B) The corresponding loading plot illustrating metabolites that contribute to 
the separation on PC1 and PC2 (see Supplementary Table S3 for the loading values). 
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Supplementary Table S4. Cell growth on YPD (1% yeast extract, 2% peptone, 2% dextrose, 
2% agar (% w/v)) and YPG (1% yeast extract, 2% peptone, 2% glycerol, 2% agar (% w/v)) 
plates, expressed as the number of colonies. Cell cultures were diluted to approximately 103 
cells/ mL, 100 µL were spread on YPD or YPG plates, and the colony number was counted 
after 2-4 days. Measurement was done in duplicate (separated by a comma) for each sampling 
point. 
Strain Plate Day 1 Day 3 Day 5 
BY4742 
YPD 86, 115 100, 100 68, 53 
YPG 81, 151 96, 112 66, 54 
rtg1∆ disruptant 
YPD 53, 52 31, 34 25, 28 
YPG 61, 62 39, 43 29, 28 
rtg3∆ disruptant 
YPD 23, 16 27, 45 6, 8 
YPG 28, 15 25, 40 10, 11 
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Supplementary Fig. S2. Intracellular (from cell extracts) and extracellular (from the growth 
medium) concentrations of glutamate and glutamine in BY4742, and rtg1∆ and rtg3∆ mutants 
(n = 3). Y-axis indicates relative intensity while x-axis indicates time. The metabolite intensities 
were relative to that of BY4742 at time 5 h. 
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Supplementary Table S5. List of disruptant strains used in this study, maximum specific 
growth rate µ (h-1) in synthetic complete medium and adenylate energy charge (EC). The 
mutants are isogenic derivatives of wild-type BY4742 (MATα leu2∆0 lys2∆0 ura3∆0 his3∆1). 
Strain  Batch 
µ (/h), 
average 
µ (/h), 
stdev 
EC (-), 
average 
EC (-), 
stdev 
BY4742(1) 1 0.47 0.04 0.75 0.02 
ace2∆ 1 0.48 0.04 0.81 0.02 
arg80∆ 1 0.49 0.05 0.72 0.06 
arg82∆ 1 0.39 0.05 0.84 0.04 
aro80∆ 1 0.52 0.03 0.76 0.02 
bas1∆ 1 0.55 0.05 0.72 0.05 
bas2/grf10/pho2∆ 1 0.51 0.02 0.76 0.03 
cad1/yap2∆ 1 0.50 0.05 0.75 0.04 
dal80∆ 1 0.52 0.04 0.78 0.03 
dal81∆ 1 0.52 0.04 0.76 0.03 
ecm22∆ 1 0.49 0.04 0.78 0.02 
fzf1∆ 1 0.48 0.06 0.76 0.04 
gcn4∆ 1 0.51 0.02 0.74 0.06 
gln3∆ 1 0.50 0.06 0.77 0.01 
gzf3∆ 1 0.47 0.04 0.74 0.04 
hap2∆ 1 0.47 0.04 0.78 0.02 
hap3∆ 1 0.50 0.05 0.76 0.04 
hap4∆ 1 0.50 0.01 0.74 0.05 
hap5∆ 1 0.52 0.08 0.79 0.00 
ime1∆ 1 0.50 0.05 0.76 0.04 
ino2∆ 1 0.30 0.02 0.86 0.00 
ino4∆ 1 0.28 0.03 0.83 0.02 
ixr1∆ 1 0.45 0.01 0.74 0.02 
leu3∆ 1 0.53 0.01 0.74 0.05 
lys14∆ 1 0.53 0.02 0.74 0.06 
met28∆ 1 0.53 0.06 0.77 0.05 
met31∆ 1 0.52 0.06 0.79 0.01 
mks1∆ 1 0.46 0.04 0.74 0.00 
mot3∆ 1 0.56 0.04 0.79 0.03 
oaf1∆ 1 0.48 0.07 0.76 0.04 
opi1∆ 1 0.24 0.01 0.83 0.02 
pho23∆ 1 0.43 0.01 0.76 0.01 
pho4∆ 1 0.51 0.03 0.79 0.02 
ric1∆ 1 0.37 0.03 0.75 0.01 
rpn4∆ 1 0.41 0.02 0.83 0.02 
sin3∆ 1 0.41 0.02 0.72 0.04 
stp1∆ 1 0.52 0.02 0.74 0.06 
stp2∆ 1 0.45 0.09 0.78 0.02 
thi2∆ 1 0.54 0.06 0.77 0.02 
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uga3∆ 1 0.52 0.02 0.75 0.03 
yap6∆ 1 0.56 0.02 0.78 0.02 
BY4742(2) 2 0.45 0.05 0.84 0.01 
adr1∆ 2 0.43 0.06 0.85 0.02 
aft2∆ 2 0.46 0.03 0.86 0.01 
arr1∆ 2 0.45 0.03 0.83 0.02 
cat8∆ 2 0.47 0.02 0.85 0.01 
cha4∆ 2 0.49 0.02 0.84 0.02 
cin5∆ 2 0.49 0.02 0.82 0.02 
crz1∆ 2 0.49 0.02 0.84 0.02 
gcr2∆ 2 0.35 0.05 0.77 0.02 
hac1∆ 2 0.45 0.04 0.86 0.02 
hal9∆ 2 0.50 0.02 0.84 0.01 
mig2∆ 2 0.49 0.02 0.86 0.01 
msn1∆ 2 0.49 0.07 0.84 0.02 
msn2∆ 2 0.51 0.07 0.80 0.04 
msn4∆ 2 0.48 0.04 0.84 0.01 
nrg1∆ 2 0.50 0.01 0.84 0.02 
pdr1∆ 2 0.47 0.04 0.85 0.02 
pdr3∆ 2 0.42 0.05 0.85 0.02 
pdr8∆ 2 0.47 0.03 0.80 0.03 
ppr1∆ 2 0.48 0.04 0.85 0.01 
rgt1∆ 2 0.49 0.05 0.82 0.05 
rim101∆ 2 0.44 0.04 0.84 0.02 
sfl1∆ 2 0.49 0.05 0.84 0.01 
sip4∆ 2 0.49 0.02 0.83 0.02 
skn7∆ 2 0.49 0.03 0.84 0.02 
sko1∆ 2 0.48 0.04 0.85 0.01 
smp1∆ 2 0.49 0.02 0.86 0.03 
stb5∆ 2 0.45 0.06 0.83 0.01 
sut1∆ 2 0.45 0.04 0.84 0.04 
swi6∆ 2 0.40 0.01 0.84 0.02 
tye7∆ 2 0.45 0.03 0.84 0.02 
ume6∆ 2 0.45 0.03 0.85 0.02 
usv1∆ 2 0.46 0.02 0.83 0.03 
wtm2∆ 2 0.48 0.06 0.83 0.04 
xbp1∆ 2 0.46 0.05 0.84 0.03 
yap1∆ 2 0.49 0.03 0.80 0.03 
yap3∆ 2 0.47 0.05 0.81 0.03 
yap5∆ 2 0.43 0.02 0.85 0.02 
yap7∆ 2 0.49 0.09 0.82 0.07 
yrm1∆ 2 0.49 0.02 0.87 0.01 
yrr1∆ 2 0.47 0.01 0.83 0.01 
BY4742(3) 3 0.48 0.03 0.83 0.01 
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ace1/cup2∆ 3 0.52 0.01 0.84 0.01 
ada2∆ 3 0.34 0.01 0.88 0.01 
ada3∆ 3 0.41 0.01 0.87 0.01 
aft1∆ 3 0.28 0.05 0.82 0.01 
argr2∆ 3 0.51 0.02 0.83 0.01 
azf1∆ 3 0.57 0.04 0.82 0.01 
cbf1∆ 3 0.37 0.04 0.84 0.01 
cst6∆ 3 0.48 0.03 0.83 0.02 
cup9∆ 3 0.51 0.02 0.83 0.02 
dal82∆ 3 0.50 0.02 0.82 0.01 
gal3∆ 3 0.52 0.01 0.83 0.01 
gal4∆ 3 0.49 0.02 0.85 0.01 
gal80∆ 3 0.52 0.02 0.83 0.02 
gat1∆ 3 0.47 0.09 0.82 0.03 
gat2∆ 3 0.53 0.06 0.82 0.02 
gat3∆ 3 0.44 0.02 0.82 0.02 
gat4∆ 3 0.43 0.04 0.81 0.03 
gis1∆ 3 0.48 0.06 0.82 0.01 
mac1∆ 3 0.46 0.03 0.81 0.01 
mal13∆ 3 0.47 0.07 0.81 0.02 
mal33∆ 3 0.53 0.04 0.82 0.00 
mga1∆ 3 0.54 0.05 0.83 0.02 
mig1∆ 3 0.43 0.06 0.81 0.02 
mig3∆ 3 0.47 0.06 0.83 0.01 
not3∆ 3 0.45 0.04 0.84 0.02 
put3∆ 3 0.44 0.03 0.82 0.01 
rgm1∆ 3 0.51 0.03 0.81 0.01 
rlm1∆ 3 0.53 0.01 0.82 0.02 
rox1∆ 3 0.50 0.03 0.82 0.01 
rsf2∆ 3 0.45 0.03 0.82 0.01 
rtg1∆ 3 0.45 0.02 0.80 0.02 
sas2∆ 3 0.46 0.01 0.81 0.02 
sef1∆ 3 0.44 0.01 0.84 0.02 
spt23∆ 3 0.50 0.04 0.83 0.01 
ssn6∆ 3 0.49 0.01 0.83 0.02 
sut2∆ 3 0.50 0.01 0.84 0.00 
tea1∆ 3 0.49 0.04 0.84 0.02 
tuf1∆ 3 0.46 0.03 0.84 0.01 
zap1∆ 3 0.48 0.06 0.81 0.00 
BY4742(4) 4 0.45 0.03 0.76 0.04 
ash1∆ 4 0.45 0.05 0.78 0.02 
ccr4∆ 4 0.47 0.03 0.77 0.03 
ezl1∆ 4 0.47 0.05 0.77 0.03 
fkh1∆ 4 0.50 0.02 0.78 0.03 
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fkh2∆ 4 0.57 0.03 0.79 0.01 
flo8∆ 4 0.49 0.01 0.80 0.00 
hcm1∆ 4 0.48 0.09 0.79 0.04 
hir1∆ 4 0.49 0.07 0.76 0.04 
hir2∆ 4 0.48 0.02 0.81 0.01 
hir3∆ 4 0.52 0.02 0.77 0.02 
hms1∆ 4 0.61 0.02 0.79 0.02 
kar4∆ 4 0.52 0.05 0.78 0.02 
mbp1∆ 4 0.42 0.02 0.79 0.01 
ndt80∆ 4 0.53 0.02 0.74 0.04 
phd1∆ 4 0.54 0.03 0.79 0.01 
rfx1∆ 4 0.54 0.03 0.75 0.08 
rph1∆ 4 0.49 0.04 0.76 0.07 
rrn10∆ 4 0.51 0.09 0.73 0.02 
rtg3∆ 4 0.47 0.07 0.74 0.06 
sds3∆ 4 0.56 0.07 0.77 0.05 
sir1∆ 4 0.49 0.03 0.81 0.01 
sir2∆ 4 0.55 0.07 0.78 0.02 
sir3∆ 4 0.52 0.03 0.81 0.01 
sir4∆ 4 0.54 0.06 0.80 0.02 
sum1∆ 4 0.46 0.11 0.74 0.08 
swi4∆ 4 0.47 0.05 0.77 0.02 
swi5∆ 4 0.50 0.02 0.77 0.02 
tec1∆ 4 0.48 0.07 0.80 0.02 
tsp1∆ 4 0.50 0.05 0.77 0.03 
uaf30∆ 4 0.49 0.04 0.78 0.01 
wtm1∆ 4 0.54 0.07 0.77 0.02 
yhp1∆ 4 0.52 0.03 0.78 0.04 
yox1∆ 4 0.52 0.03 0.79 0.01 
zds1∆ 4 0.50 0.03 0.78 0.03 
zds2∆ 4 0.51 0.01 0.79 0.02 
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Supplementary Table S6. Summary of PCA with eleven significant components performed 
for metabolome dataset from metabolic profiling of 154 deletion strains. 
Component R2X 
R2X 
(cum) 
Eigen 
value 
Q2 Limit 
Q2 
(cum) 
Significance Iterations 
0 Non-Cent.               
1 0.366 0.366 11.5 0.252 0.0118 0.252 R1 16 
2 0.173 0.539 18.1 0.155 0.0119 0.368 R1 12 
3 0.0696 0.608 8.25 0.00218 0.012 0.37 R2 52 
4 0.0576 0.666 6.8 0.07 0.0122 0.414 R1 37 
5 0.0425 0.708 4.92 -0.035 0.0123 0.393 R2 52 
6 0.036 0.744 4.24 0.0349 0.0125 0.414 R1 40 
7 0.0303 0.775 3.58 0.0432 0.0127 0.44 R1 60 
8 0.0241 0.799 2.83 -8.74x10-5 0.0128 0.44 R2 46 
9 0.0203 0.819 2.39 -0.00329 0.013 0.438 R2 117 
10 0.0186 0.838 2.21 0.0157 0.0132 0.447 R1 70 
11 0.0158 0.853 1.87 -0.0157 0.0133 0.438 R2 39 
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Supplementary Table S7. List of metabolites and the number of deletion strains (out of 154) 
that were significantly changed or unchanged compared with wild-type BY4742 (p-value < 
0.05).  
 No. of strains  No. of strains 
Metabolite Changed Unchanged Metabolite Changed Unchanged 
Arginine 111 43 Succinate 63 91 
Histidine 115 39 Fumarate 4 150 
Serine 15 139 cAMP 7 147 
Asparagine 5 149 Malate 44 110 
Glutamine 21 133 UDP-Glucose 59 95 
Homoserine 25 129 2-Oxoglutarate 49 105 
Threonine 41 113 CDP 16 138 
Trehalose 3 151 GDP 3 151 
Proline 23 131 NADP 7 147 
Valine 8 146 F2,6P 9 145 
Methionine 5 149 F1,6P 8 146 
Guanine 126 28 Isocitrate 16 138 
Isoleucine 12 142 Citrate 19 135 
Tyrosine 5 149 ADP 9 145 
Amino adipic acid 22 132 1,3-BPG 15 139 
Glutamate 16 138 Phosphoenolpyruvate 12 142 
Aspartate 16 138 FMN 10 144 
Inosine 135 19 2-Isopropylmalate 32 122 
Guanosine 132 22 FAD 3 151 
Phenylalanine 3 151 CTP 45 109 
Pyroglutamate 2 152 GTP 14 140 
Glucose 6-phosphate 11 143 NADPH 5 149 
Ribose 5-phosphate 19 135 UTP 54 100 
Sedoheptulose 7P 21 133 ATP 14 140 
Fructose 6-phosphate 2 152 Acetyl CoA 20 134 
Tryptophan 14 140 Alanine 12 142 
α-Glycerophosphate 39 115 Glycine 7 147 
Glutathione 7 147 2-Aminoethanol 5 149 
GAP 11 143 Urea 3 151 
Ribulose 5-phosphate 18 136 Phosphate 13 141 
Orotate 32 122 Glycerol 27 127 
Fructose 1-phosphate 19 135 Leucine 6 148 
CMP 10 144 Uracil 6 148 
NAD 8 146 Lysine 92 62 
Pyruvate 27 127 Adenine 45 109 
DHAP 14 140 Inositol 9 145 
UMP 24 130 Octadecanoate 4 150 
GMP 11 143 Cysteine+Cystine 6 148 
Oxalacetate 29 125 Citrulline 48 106 
AMP 14 140 Glucose 15 139 
Nicotinate 40 114 β-Lactose 14 140 
Pantothenate 26 128 Melibiose 2 152 
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